ISOLATED ANTIBODY OR ANTIGEN-BINDING PORTION OF IT THAT BINDS TO HUMAN 4-1BB, COMBINATION, USES THER

专利摘要:
4-1bb binding molecules. the present invention provides isolated binding molecules that bind to 4-1bb, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, methods for producing the binding molecules, pharmaceutical compositions containing binding molecules and methods of using the binding molecules or compositions.
公开号:BR112013005699B1
申请号:R112013005699-1
申请日:2011-08-26
公开日:2021-08-17
发明作者:Bianca AHRENS；Sangita M. Baxi；Simon Paul Bergqvist；Regis Doyonnas；Robert Lee Dufield；Mark William Elliott；Timothy Scott Fisher；Richard Michael Jerome；Heather Laurence Jones；Cris Kamperschroer；Victoria Alexandria Love；Kathrin Ladetzki-Baehs；Theodore Lawrence Oliphant；Adekunle Olatunbosun Onadipe；Wenning Qin；Vinay Radhakrishnan；Allison Karlyn Rohner；Leslie Lynne Sharp；Michael Tesar；Kristin Elizabeth Thomas；Libbey Anne Yates；Daisy Marie Ziegemeier；Moritz ZULLEY
申请人:Pfizer Inc；
IPC主号:

专利说明:

field of invention
[001] The present invention relates to antibodies and especially to antibodies that bind to human 4-1BB. Background of the invention
[002] The 4-1BB transmembrane protein (also called CD137, TNFRSF9, etc.) belongs to the Tumor Necrosis Factor Receptor (TNFRS) superfamily. Current understanding of 4-1BB indicates that expression depends in general on activation and its presence in a vast subset of immune cells, including NK and NKT cells, regulatory T cells, dendritic cells (DC), stimulated mast cells, myeloid cells in differentiation, monocytes, neutrophils and eosinophils (Wang, 2009, Immunological Reviews 229: 192-215). The expression of 4-1BB has also been demonstrated in tumor vessels (Broll, 2001, Amer. J Clin. Pathol. 115(4):543-549; Seaman, 2007, Cancer Cell 11: 539-554) and affected endothelial sites by inflammation or atherosclerosis (Drenkard, 2007 FASEB J. 21: 456-463; Olofsson, 2008, Circulation 117: 1292-1301). The 4-1BB-stimulating ligand, that is, the 4-1BB Ligand (4-1BBL), is also expressed in activated antigen-presenting cells (APCs), myeloid progenitor cells, and hematopoietic stem cells.
[003] The 4-1BB protein is formed by 255 amino acids (Accession No. NM_001561; NP_001552). The complete amino acid sequence of human 4-1BB is provided in SEQ ID NO: 68. The protein comprises a signal sequence (amino acid residues 1-17), followed by an extracellular domain (169 amino acids), a transmembrane region (27 amino acids) and an intracellular domain (42 amino acids) (Cheuk ATC et al. 2004 Cancer Gene Therapy 11: 215-226). The receptor is expressed on the cell surface as monomers and dimers and is likely to trimerize with the 4-1BB ligand to initiate signaling.
[004] Numerous murine and human T cell studies indicate that the 4-1BB protein enhances cell proliferation, survival and cytokine production (Croft, 2009, Nat Rev Immunol 9:271-285). Studies have shown that some agonistic MAbs against 4-1BB increase the expression of costimulatory molecules and markedly reinforce cytolytic T lymphocyte responses, resulting in antitumor efficacy in several models. Agonist MAbs against 4-1BB have demonstrated efficacy in prophylactic and therapeutic settings. In addition, tumor models of monotherapy and combination therapy with 4-1BB have established the presence of long-lasting anti-tumor protective responses by memory T cells (Lynch, 2008, Immunol Rev. 22: 277-286). 4-1BB agonists have also been shown to inhibit autoimmune reactions in a variety of art-recognized models of autoimmunity (Vinay, 2006, J Mol Med 84:726-736). This dual activity of 4-1BB offers the potential for antitumor action while dampening autoimmune side effects that may be associated with immunotherapy approaches, attributed to the breakdown of immune tolerance.
[005] There is a long-felt unmet need for antibodies that bind to the human 4-1BB protein, enhance the 4-1BB-mediated response and thereby offer therapeutic potential for the treatment of various diseases and conditions, including cancer. Invention Summary
[006] The present invention aims to provide an isolated binding molecule that binds to human 4-1BB, such as an antibody or binding fragment or derivative thereof. Another object of the present invention is to provide a composition containing a binding molecule that binds to 4-1BB. Additionally, the present invention aims to provide methods for treating a disease and/or condition associated with or mediated by 4-1BB signaling via one or more binding molecules of the invention. These and other objects of the invention are described in more detail in this patent application.
In some aspects, the invention provides isolated antibodies that bind to human 4-1BB.
In a specific aspect, the isolated antibody binds to human 4-1BB at an epitope comprising amino acid residues 115 - 156 of SEQ ID NO: 68. In some specific embodiments, the antibody comprises the amino acid sequence of H-CDR1 of SEQ ID NO:29, the amino acid sequence of H-CDR2 of SEQ ID NO:30, and the amino acid sequence of H-CDR3 of SEQ ID NO:31. In other specific embodiments, the antibody comprises the L-CDR1 amino acid sequence of SEQ ID NO: 34, L-CDR2 amino acid sequence of SEQ ID NO: 35 the L-CDR3 amino acid sequence of SEQ ID NO: 36.
[009] In another specific aspect, the isolated antibody binds to human 4-1BB with KD of 600 nM or less, 100 nM or less, 50 nM or less, 10 nM or less, 5 nM or less or 1 nM or less, for the extracellular domain of human 4-1BB, as measured with the BIACore assay described in this invention.
In another specific aspect, the isolated antibody comprises: (a) an H-CDR1 as set forth in SEQ ID NO:1, SEQ ID NO:15 or SEQ ID NO:29; (b) an H-CDR2 as set forth in SEQ ID NO: 2, SEQ ID NO: 16 or SEQ ID NO: 30; and (c) an H-CDR3 as set forth in SEQ ID NO: 3, SEQ ID NO: 17 or SEQ ID NO: 31.
In another specific aspect, the isolated antibody comprises: (a) an L-CDR1 as set forth in SEQ ID NO:6, SEQ ID NO:20 or SEQ ID NO:34; (b) an L-CDR2 as set forth in SEQ ID NO: 7, SEQ ID NO: 21 or SEQ ID NO: 35; and (c) an L-CDR3 as set forth in SEQ ID NO: 8, SEQ ID NO: 22, SEQ ID NO: 36 or SEQ ID NO: 55.
In a further aspect, the isolated antibody comprises: (a) an H-CDR1 as set forth in SEQ ID NO: 1, SEQ ID NO: 15 or SEQ ID NO: 29; (b) an H-CDR2 as set forth in SEQ ID NO: 2, SEQ ID NO: 16 or SEQ ID NO: 30; and (c) an H-CDR3 as set forth in SEQ ID NO: 3, SEQ ID NO: 17 or SEQ ID NO: 31; and further comprises: (d) an L-CDR1 as set forth in SEQ ID NO: 6, SEQ ID NO: 20 or SEQ ID NO: 34; (e) an L-CDR2 as set forth in SEQ ID NO: 7, SEQ ID NO: 21 or SEQ ID NO: 35; and (f) an L-CDR3 as set forth in SEQ ID NO: 8, SEQ ID NO: 22, SEQ ID NO: 36 or SEQ ID NO: 55.
[0013] In some other specific aspects, the isolated antibody is selected from the group consisting of: (a) an antibody or antigen-binding part thereof, comprising: an H-CDR1 as shown in SEQ ID NO: 1, an H-CDR2 as shown in SEQ ID NO:2, and an H-CDR3 as shown in SEQ ID NO:3; (b) an antibody or antigen-binding part thereof, comprising an H-CDR1 as shown in SEQ ID NO: 15, an H-CDR2 as shown in SEQ ID NO: 16, and an H-CDR3 as shown in SEQ ID NO: 17, and (c) an antibody or antigen-binding part thereof, comprising an H-CDR1 as shown in SEQ ID NO: 29, an H-CDR2 as shown in SEQ ID NO: 30, and an H-CDR3 as shown in SEQ ID NO: 31.
[0014] In some further aspects, the invention provides an isolated antibody or antigen-binding part thereof, which specifically binds to human 4-1BB, wherein said antibody or antigen-binding part is selected from the constituted group by: (a) an antibody or antigen-binding part thereof, comprising an L-CDR1 as shown in SEQ ID NO: 6, an L-CDR2 as shown in SEQ ID NO: 7 and an L-CDR3 as shown in SEQ ID NO: 8. (b) an antibody or antigen-binding part thereof, comprising an L-CDR1 as shown in SEQ ID NO:20, an L-CDR2 as shown in SEQ ID NO:21 and an L-CDR3 as shown in SEQ ID NO: 22. (c) an antibody or antigen-binding part thereof, comprising an L-CDR1 as shown in SEQ ID NO: 34, an L-CDR2 as shown in SEQ ID NO: 35 and an L -CDR3 as shown in SEQ ID NO: 36; and (d) an antibody or antigen binding part thereof, comprising an L-CDR1 as shown in SEQ ID NO:34, an L-CDR2 as shown in SEQ ID NO:35 and an L-CDR3 as shown in SEQ ID NO: 55.
[0015] In some other specific aspects, the isolated antibody is selected from the group consisting of: (a) an antibody or antigen-binding part thereof, comprising: an H-CDR1 as shown in SEQ ID NO:1, a H-CDR2 as shown in SEQ ID NO:2, an H-CDR3 as shown in SEQ ID NO:3; an L-CDR1 as shown in SEQ ID NO: 6, an L-CDR2 as shown in SEQ ID NO: 7 and an L-CDR3 as shown in SEQ ID NO: 8; (b) an antibody or antigen-binding part thereof, comprising an H-CDR1 as shown in SEQ ID NO: 15, an H-CDR2 as shown in SEQ ID NO:16, an H-CDR3 as shown in SEQ ID NO: : 17; an L-CDR1 as shown in SEQ ID NO: 20, an L-CDR2 as shown in SEQ ID NO: 21 and an L-CDR3 as shown in SEQ ID NO: 22. (c) an antibody or binding part thereof antigen, comprising an H-CDR1 as shown in SEQ ID NO: 29, an H-CDR2 as shown in SEQ ID NO: 30, an H-CDR3 as shown in SEQ ID NO: 31; an L-CDR1 as shown in SEQ ID NO: 34, an L-CDR2 as shown in SEQ ID NO: 35 and an L-CDR3 as shown in SEQ ID NO: 36; and (d) an antibody or antigen binding part thereof, comprising an H-CDR1 as shown in SEQ ID NO: 29, an H-CDR2 as shown in SEQ ID NO: 30, an H-CDR3 as shown in SEQ ID NO: 31; an L-CDR1 as shown in SEQ ID NO: 34, an L-CDR2 as shown in SEQ ID NO: 35 and an L-CDR3 as shown in SEQ ID NO: 55.
In a specific further aspect, the isolated antibody comprises a VH amino acid sequence in the chain as set forth in SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:32 and SEQ ID NO:43.
In a specific further aspect, the isolated antibody comprises an amino acid sequence of VL in the chain as shown in SEQ ID NO: 9, SEQ ID NO: 23, SEQ ID NO: 37, SEQ ID NO: 45, SEQ ID NO: 51, SEQ ID NO: 56, SEQ ID NO: 60 or SEQ ID NO: 64.
In a further specific aspect, the isolated antibody is a VH domain amino acid sequence as set forth in any one of SEQ ID NOs: 4, 18, 32 and :43 and further comprises a VL domain amino acid sequence as set out in any one of SEQ ID NOs: 9, SEQ ID NO: 23, SEQ ID NO: 37, SEQ ID NO: 45, SEQ ID NO: 51, SEQ ID NO: 56, SEQ ID NO: 60 and SEQ ID NO: 64
[0019] In a specific further aspect, the isolated antibody is selected from the group consisting of: (a) an antibody comprising a VH amino acid sequence in the chain as shown in SEQ ID NO: 4 and a VL amino acid sequence in the chain as shown in SEQ ID NO: 9; (b) an antibody comprising an in-chain VH amino acid sequence as shown in SEQ ID NO:18 and an in-chain VL amino acid sequence as shown in SEQ ID NO:23; (c) an antibody comprising an in-chain VH amino acid sequence as shown in SEQ ID NO: 32 and an in-chain VL amino acid sequence as shown in SEQ ID NO: 37 or SEQ ID NO: 56; and (d) an antibody comprising an in-chain VH amino acid sequence as shown in SEQ ID NO: 43 and an in-chain VL amino acid sequence as shown in SEQ ID NO: 45, SEQ ID NO: 51, SEQ ID NO. :60 or SEQ ID NO:64.
In yet another specific aspect, the isolated antibody provided by the present invention comprises a VH chain which is encoded by (i) a nucleic acid sequence comprising SEQ ID NO: 11, SEQ ID NO: 25, SEQ ID NO: 39, SEQ ID NO: 47 or (ii) nucleic acid sequences which hybridize under high stringency conditions to the complementary strand of SEQ ID NO: 11, SEQ ID NO: 25, SEQ ID NO: 39 or SEQ ID NO: 47.
In yet another specific aspect, the isolated antibody comprises a VL chain that is encoded by (i) a nucleic acid sequence comprising SEQ ID NO: 12, SEQ ID NO: 26, SEQ ID NO: 40, SEQ ID NO: 48, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 62 or SEQ ID NO: 66 or (ii) nucleic acid sequences which hybridize under high stringency conditions to the complementary strand of the SEQ ID NO: 12, SEQ ID NO: 26, SEQ ID NO: 40, SEQ ID NO: 48, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 62 or SEQ ID NO: 66.
[0022] In a specific further aspect, an isolated antibody is provided that competes and/or cross-competes for binding to human 4-1BB with an illustrative antibody selected from MOR-6032, MOR-7361, MOR-7480, MOR-7480.1, MOR-7480.2, MOR 7483, MOR-7483.1 or MOR-7483.2.
In a further specific aspect, an isolated antibody is provided which binds to the same epitope on human 4-1BB as any of the antibodies to the antibodies described in this patent application. In some embodiments, the invention provides isolated antibody that binds to the same epitope on human 4-1BB as an illustrative antibody selected from MOR-6032, MOR-7361, MOR-7480, MOR-7480.1, MOR-7480.2, MOR 7483 , MOR-7483.1 or MOR-7483.2.
[0024] In a further specific aspect, the present invention provides an isolated antibody that binds to human 4-1BB, comprising a heavy chain variable region, which is the product or derived from a VH 3-23 gene, gene VH 1-69 or human VH 5 . In another specific aspect, the present invention provides an isolated antibody that binds to human 4-1BB, comprising a light chain variable region that is the product of or is derived from a human À3 or À1-13 VL gene.
In some embodiments, the isolated antibodies described herein have one or more of the following properties or characteristics: a) specifically bind to human 4-1BB; b) bind to human or cynomolgus 4-1BB; c) bind to human 4-1BB or cynomolgus 4-1BB, but not rat or mouse 4-1BB; d) are IgG, such as IgG1, IgG2, IgG3 or IgG4; and e) are human antibodies or humanized antibodies.
In some other aspects, the present invention provides an antigen-binding portion of any of the antibodies provided by the present invention. In some embodiments, the antigen-binding portion is the Fab or scFv fragment.
In some additional aspects, the present invention provides a derivative of any of the antibodies provided by the present invention.
[0028] In some other aspects, the invention provides an isolated nucleic acid encoding a VH chain of an antibody or antigen-binding part thereof that binds to human 4-1BB, which is selected from the consisting group. by: (i) a nucleic acid sequence encoding a VH amino acid sequence in the chain as set forth in SEQ ID NO: 4, SEQ ID NO: 18, SEQ ID NO: 32 or SEQ ID NO: 43; (ii) a nucleic acid sequence as set forth in SEQ ID NO: 11, SEQ ID NO: 25, SEQ ID NO: 39 or SEQ ID NO: 47; or (iii) a nucleic acid sequence which hybridizes under high stringency conditions to the complementary strand of a nucleic acid sequence as set forth in SEQ ID NO: 11, SEQ ID NO: 25, SEQ ID NO: 39 or SEQ ID NO: 47.
[0029] In some other aspects, the invention provides an isolated nucleic acid encoding a VL chain of an antibody or antigen-binding part thereof that binds to human 4-1BB, which is selected from the consisting group. by: (i) a nucleic acid sequence encoding an amino acid sequence of VL in the chain as shown in SEQ ID NO: 9, SEQ ID NO: 23, SEQ ID NO: 37, SEQ ID NO: 45, SEQ ID NO :51, SEQ ID NO:56, SEQ ID NO:60 or SEQ ID NO:64; (ii) a nucleic acid sequence as set forth in SEQ ID NO: 12, SEQ ID NO: 26, SEQ ID NO: 40, SEQ ID NO: 48, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO :62 or SEQ ID NO:66; or (iii) nucleic acid sequences which hybridize under high stringency conditions to the complementary strand of a nucleic acid sequence as set forth in SEQ ID NO: 12, SEQ ID NO: 26, SEQ ID NO: 40, SEQ ID NO :48, SEQ ID NO:53, SEQ ID NO:58, SEQ ID NO:62 or SEQ ID NO:66.
In some additional aspects, the invention provides a vector comprising any of the nucleic acids described herein. In a still further aspect, the invention provides a host cell comprising any of the vectors described herein. Such host cells can be bacterial or mammalian.
[0031] In some further aspects, the invention provides a pharmaceutical composition comprising any of the antibodies, its antigen-binding parts or its derivatives and a pharmaceutically acceptable carrier.
The invention further provides methods for treating abnormal cell growth in an individual in need of such treatment, comprising administering to the individual an effective amount of a binding molecule of the invention or a pharmaceutical composition described herein. The invention further provides methods of reducing tumor cell metastasis in an individual, comprising administering to said individual an effective amount of a binding molecule or pharmaceutical compositions described herein.
[0033] In a further aspect, the invention provides the use of any of the binding molecules or a pharmaceutical composition described herein, for the manufacture of a medicament for the treatment of abnormal cell growth in an individual in need thereof. In a further aspect, the invention provides a binding molecule or pharmaceutical composition, as described herein, for use in treating abnormal cell growth in an individual in need thereof. In a still further aspect, the invention provides a binding molecule or pharmaceutical composition, as described herein, for use in treating tumor cell metastasis in an individual in need thereof. In a still further aspect, the invention provides the use of any of the binding molecules or a pharmaceutical composition described herein for the manufacture of a medicament for the treatment of tumor cell metastasis in an individual in need thereof. Brief description of the drawings
[0034] Figure 1 presents four column graphs showing the mean fluorescence intensity of unstimulated (black) and PHA-stimulated (light gray) primary PBMCs from humans (top left), cynomolgus (top right), dog (bottom left) and rat (bottom right), which were incubated with the indicated antibody against 4-1BB or the control antibody conjugated to Alexafluor 647. Panel demonstrates binding to PHA-stimulated human and cynomolgus PBMC .
[0035] Figure 2 presents two line graphs showing the luciferase reporter activity in 293T cells expressing 4-1BB and which were stimulated with various concentrations of specific mAb against 4-1BB or of isotype control mAb. Left panel demonstrates reporter activity in cynomolgus 4-1BB expressing cells. The right panel demonstrates activity in cells expressing human 4-1BB. Data are expressed as a function of the number of times of stimulation above the control isotype.
[0036] Figure 3 (3A and 3B) shows line graphs showing the concentration of human IL-2 present in cell culture media after 72 hours of stimulation of human T cells with anti-CD3 and various concentrations of antibodies against 4- 1BB. Each panel (A and B) represents an individual donor.
[0037] Figure 4 is a scatter diagram showing the expansion of human peripheral blood mononuclear cells in mice that were treated with mAb against 4-1BB or with the isotype control mAb. Data are expressed as the percentage of cells expressing human CD45 in the peripheral blood of individual NSG mice on Days 24-28 of the study that had been injected with six million human peripheral blood mononuclear cells on Day 0 and injected with mAb against 4 -1BB 1 mg/kg or with isotype control mAb on Day 9. Statistical significance was determined using the two-way Mann-Whitney test: * p<0.05, ** p<0.005. No HBPT refers to animals that have not been injected with human cells.
[0038] Figure 5 presents two column graphs showing the change in proliferating CD8 memory T cells that occurred at various time points after administration of mAb against 4-1BB in cynomolgus monkeys. Data are shown in columns representing animals designated as (dose level-animal number) and are represented as intra-animal change in Ki-67+ cell number from pre-study number {[(Ki- cell number) 67+ on indicated study day - no of Ki-67+ cells before dose)/no of Ki-67+ cells before dose]*100}. CD8 memory core cells have been identified as CD3+, CD8+, CD28+ and CD95+.
[0039] Figure 6 presents line graphs showing the growth of tumors injected subcutaneously with tumor cells (PC3, left panel; LOVO, right panel) and human peripheral blood mononuclear cells on Day 0 of the study. Mice were injected with 10 mg/kg of the indicated mAbs against 4-1BB on Day 0.
[0040] The left panel of Figure 7 is a scatter plot showing the percentage of PBMC that are positive for the CD8+ T cell surface marker and that have incorporated the nucleoside analogue BrdU after treatment of knock in mice (with gain of function) of 4-1BB with mAb against 4-1BB or vehicle control. The right panel is a line graph showing the growth of subcutaneously injected murine melanoma tumors in 4-1BB knock in mice and treated with the indicated concentration of mAb against 4-1BB.
[0041] Figure 8 shows Amino Acid Sequence alignments of the Heavy Chain Variable Regions and the Chain Variable Regions (with the CDRs underlined) with the Relevant Germinative Lineage Sequences. Detailed description of the invention A. Definitions
[0042] Unless otherwise defined in this specification, scientific and technical terms used within the scope of the present invention will have the meanings that are commonly understood by those skilled in the art. In addition, unless otherwise required by the context, singular terms will include pluralities and plural terms will include the singular. In general, the nomenclatures used in relation to and with techniques of cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described in this patent application are those well known and commonly used in technique.
[0043] In this descriptive report, each of the following terms have the meanings they are associated with in this section.
The term "antibody against 4-1BB" refers to an antibody, as defined in this specification, capable of binding to the human 4-1BB receptor.
The terms "4-1BB" and "4-1BB receptor" are used interchangeably in the present application, including the human 4-1BB receptor, as well as cross-species variants, isoforms and homologues thereof. Thus, a binding molecule, as defined and disclosed in this specification, can also bind to 4-1BB from species other than humans. In other cases, a binding molecule may be completely specific for human 4-1BB and may not exhibit cross-species cross-reactivity or other types of cross-reactivity.
[0046] The articles "a" and "an" refer to one or more than one (ie, at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0047] The term "agonist" refers to a binding molecule, as defined in this specification, which, upon binding to 4-1BB, (1) stimulates or activates 4-1BB, (2) intensifies, increases , promotes, induces or prolongs an activity, function or presence of 4-1BB or (3) enhances, increases, promotes or induces the expression of 4-1BB.
The term "amino acid" refers to natural and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that operate in a similar manner to natural amino acids. Natural amino acids are those encoded by the genetic code, as well as those that are modified later, for example, hydroxyproline, gamma-carboxyglutamate and O-phosphoserine. The term "amino acid analogue" refers to compounds that have the same basic chemical structure as a natural amino acid, but whose C-terminal carboxy group, N-terminal amino group, or a side chain functional group has been modified. chemically to another functional group. The term "amino acid mimetic" refers to chemical compounds that have a structure different from the general chemical structure of an amino acid, but that operate in a similar way to a natural amino acid.
[0049] The term "antibody" is an art-recognized term and refers to an antigen-binding protein (ie, immunoglobulin) with a basic structure formed by four polypeptide chains, consisting of two identical heavy (H) chains and two identical light (L) chains. Each L chain is joined to an H chain by a covalent disulfide bond, while the two H chains are joined together by one or more disulfide bonds depending on the isotype of the H chain. Each heavy chain has, at the N-terminus, a variable region (abbreviated in this descriptive report as VH) followed by a constant region. The heavy chain constant region is composed of three domains, CH1, CH2 and CH3. Each light chain has, at the N-terminus, a variable region (abbreviated in this report as VL) followed by a constant region at its other end. The constant region of the light chain is composed of a domain, CL. The VL is aligned with the VH and the CL is aligned with the first constant domain of the heavy chain (CH1). The pairing of a VH and a VL together form a single antigen-binding site. An IgM antibody is composed of 5 of the basic heterotetrameric units, together with an additional polypeptide called the J chain and therefore contains 10 antigen-binding sites, while secreted IgA antibodies can polymerize to form polyvalent assemblies comprising 2-5 of the 4-chain basic units along with J-chain.
[0050] The VH and VL regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDR), interspersed with regions that are more conserved, called framework (framework) regions (FR). CDR regions can be determined using the Kabat or Chothia numbering systems, both of which are well known to those skilled in the art. See, for example, Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242; Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987). The VH and VL are composed of three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Throughout this report, the three heavy chain CDRs are referred to as H-CDR1, H-CDR2 and H-CDR3. Likewise, the three light chain CDRs are referred to as L-CDR1, L-CDR2 and L-CDR3. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. Antibody constant regions can mediate immunoglobulin binding to host tissues or factors, including various cells of the immune system (eg, effector cells) and the first component (Clq) of the classical complement system. Within the light and heavy chains, the variable and constant regions are joined by a "J" region of approximately 12 or more amino acids, the heavy chain also including a "D" region of approximately 10 or more amino acids. See generally, Fundamental Immunology, chapter 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989)).
[0051] The L chain of any vertebrate species can be assigned to one of two clearly distinct types, termed kappa and lambda, based on the amino acid sequences of its constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains (CH), antibodies can be assigned to different classes or isotypes. There are five classes of antibodies: IgA, IgD, IgE, IgG and IgM, with heavy chains designated α (alpha), δ (delta), ε (epsilon), Y (gamma) and μ (mu), respectively. The IgG class of antibody can be further classified into four IgG1, IgG2, IgG3 and IgG4 subclasses by the gamma heavy chains, Y1 - Y4, respectively.
The term "antibody-derived" or "derived" of an antibody refers to a molecule that is capable of binding the same antigen (eg, 4-1BB) as the antibody binds to and comprises a sequence of antibody amino acids linked to an additional molecular entity. The antibody amino acid sequence which is contained in the antibody derivative may be the entire heavy chain, the entire light chain, any part or parts of an entire heavy chain, any part or parts of the antibody light chain, any other fragments of an antibody of the complete antibody. The additional molecular entity can be a chemical or biological molecule. Examples of additional molecular entities include chemical groups, amino acids, peptides, proteins (such as enzymes, antibodies) and chemical compounds. The additional molecular entity may have any utility, such as for use as a detecting, labeling, labeling, pharmaceutical or therapeutic agent. The amino acid sequence of an antibody can be tethered or linked to the additional molecular entity by chemical coupling, genetic fusion, non-covalent association, or otherwise. The term "antibody derivative" also encompasses chimeric antibodies, humanized antibodies and molecules that are derived from modifications to the amino acid sequences of an antibody against 4-1BB, such as conservative amino acid substitutions, additions and insertions.
[0053] The term "antigen-binding fragment" or "antigen-binding part" of an antibody refers to one or more parts of an antibody that retain the ability to bind to the antigen to which the antibody binds ( for example, 4-1BB). Examples of an "antigen-binding fragment" of an antibody include (i) Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) F(ab')2 fragment, a bivalent fragment comprising two Fab fragments joined by a disulfide bridge at the hinge region; (iii) Fd fragment consisting of the VH and CH1 domains; (iv) Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) dAb fragment (Ward et al., Nature 341:544-546 (1989)), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR).
The term "binding molecule" encompasses (1) antibody, (2) antigen-binding fragment of an antibody, and (3) derived from an antibody, each as defined in this specification.
[0055] The term "bind 4-1BB", "bind 4-1BB", "bind 4-1BB" or "bind 4-1BB" refers to the binding of a binding molecule, such as defined herein, to human 4-1BB in an in vitro assay, such as the BIAcore assay as described in Example 6, with an affinity (KD) of 500 nM or less.
The term "chimeric antibody" refers to an antibody comprising amino acid sequences derived from different animal species, such as those having a variable region derived from a human antibody and a constant region from murine immunoglobulin.
The term "compete for binding" refers to the interaction of two antibodies in their binding to a binding target. A first antibody competes for binding with a second antibody, if the binding of the first antibody with its cognate epitope detectably decreases in the presence of the second antibody, compared to binding of the first antibody in the absence of the second antibody. The alternative, where the binding of the second antibody to its epitope also decreases detectably in the presence of the first antibody, may, but need not be, the case. That is, a first antibody can inhibit the binding of a second antibody to its epitope without the second antibody inhibiting the binding of the first antibody to its respective epitope. However, when each antibody detectably inhibits the binding of the other antibody to its cognate epitope, whether the same, to a greater or lesser extent, the antibodies are said to "cross-compete" with each other for binding to their(s) respective epitope(s).
The term "epitope" refers to a part of an antigen to which an antibody (or its antigen-binding fragment) binds. Epitopes can be formed either from contiguous amino acids or non-contiguous amino acids juxtaposed by the tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope can include multiple numbers of amino acids in a unique spatial conformation. Methods for determining the spatial conformation of epitopes include, for example, x-ray crystallography and two-dimensional nuclear magnetic resonance. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. Morris, Ed. (1996). Once a desired epitope or antigen is determined, antibodies against that epitope can be generated, for example, using the techniques described herein. Antibody generation and characterization can also elucidate information about desirable epitopes. From this information, it is then possible to competitively screen for antibodies that bind to the same epitope. One approach to accomplishing this is to conduct cross-competition studies to discover antibodies that competitively bind to each other, that is, the antibodies compete for binding to the antigen. A high-throughput process for "compartmentalizing" antibodies on the basis of their cross-competition is described in PCT Publication No. WO 03/48731.
[0059] The term "germ line" refers to the nucleotide sequences of antibody genes and gene segments as they are transmitted from parent to offspring via germ cells. The germline sequence is distinguished from nucleotide sequences encoding antibodies in mature B cells that have been altered by recombination and by hypermutation events in the course of B cell maturation.
[0060] The term "glycosylation sites" refers to amino acid residues that are recognized by a eukaryotic cell as sites for attachment of sugar residues. The amino acids to which carbohydrate, such as an oligosaccharide, is attached are typically the residues asparagine (N-linked), serine (O-linked) and threonine (O-linked). The specific docking site is typically signaled by an amino acid sequence, referred to in this specification as the "glycosylation site sequence". The glycosylation site sequence for N-linked glycosylation is: -Asn-X-Ser- or -Asn-X-Thr-, where X can be any of the conventional amino acids, with the exception of proline. The terms "N-attached" and "O-attached" refer to the chemical group that serves as the coupling site between the sugar molecule and the amino acid residue. N-linked sugars are coupled through an amino group; O-linked sugars are coupled through a hydroxyl group. The term "glycan occupancy" refers to the existence of a carbohydrate group that is attached to a glycosylation site (i.e., the glycan site is occupied). When there are at least two potential glycosylation sites on a polypeptide, none (0 glycan site occupation), one (1 glycan site occupation) or both (2 glycan site occupation) the sites may be occupied by a group carbohydrate.
[0061] The term "host cell" refers to a cellular system that can be constructed to generate proteins, protein fragments or peptides of interest. Host cells include, but are not limited to, cultured cells, for example, cultured mammalian cells derived from rodents (rats, mice, guinea pigs or hamsters) such as CHO, BHK, NSO, SP2/0, YB2/0; or cells from human tissues or from hybridomas, yeast cells and insect cells included in a transgenic animal or cultured tissue. The term covers not only the specific cell in question, but also the progeny of that cell. Since certain modifications can occur in succeeding generations due to mutation or environmental influences, such progeny may not be identical to precursor cells, but are still included within the scope of the term "host cell".
The term "human antibody" refers to an antibody in which the entire light and heavy chain amino acid sequences are derived from human immunoglobulin genes. A human antibody can contain murine carbohydrate chains if produced in a mouse, in a mouse cell, or in a hybridoma derived from a mouse cell. Human antibodies can be prepared in a variety of ways known in the art.
The term "humanized antibody" refers to a chimeric antibody that contains amino acid residues derived from human antibody sequences. A humanized antibody may contain some or all of the CDRs of a non-human animal antibody, while the framework and constant regions of the antibody contain amino acid residues derived from human antibody sequences.
The term "illustrative antibody" refers to any of the antibodies described in the invention and designated MOR-6032, MOR-7361, MOR-7480, MOR-7480.1, MOR-7480.2, MOR-7483, MOR-7483.1 and MOR-7483.2. These antibodies can be of any class (for example, IgA, IgD, IgE, IgG and IgM). Therefore, every antibody identified above encompasses antibodies in all five classes that have the same amino acid sequences for the VL and VH regions. Also, antibodies in the IgG class can be in any subclass (for example, IgG1 IgG2, IgG3 and IgG4). Therefore, every antibody identified above in the IgG subclass encompasses antibodies in all four subclasses that have the same amino acid sequences for the VL and VH regions. The amino acid sequences of the constant regions of the heavy chain of human antibodies in the five classes, as well as the four IgG subclasses, are known in the art. As examples, the amino acid sequences of the constant regions of human IgG1 and IgG2 are provided in SEQ ID NOs: 69 and 71, respectively. The complete heavy chain amino acid sequence for the IgG2 subclass of each of the illustrative antibodies is provided in the invention.
[0065] The term "isolated antibody" or "isolated binding molecule" refers to an antibody or binding molecule, as defined in this specification, which: (1) is not associated with naturally associated components that accompany it in your native state; (2) is free of other proteins of the same species; (3) is expressed by a cell of a different species; or (4) does not occur in nature. Examples of isolated antibodies include a 4-1BB antibody that was affinity purified using 4-1BB, a 4-1BB antibody that was generated by hybridomas or another cell line in vitro, and a 4-1BB antibody derived from a transgenic animal.
The term "isolated nucleic acid" refers to a nucleic acid molecule of genomic, cDNA or synthetic origin, or a combination thereof, which is separated from other nucleic acid molecules present in the natural source of the nucleic acid. For example, with regard to genomic DNA, the term "isolated" includes nucleic acid molecules that are separated from the chromosome with which the genomic DNA is naturally associated. Preferably, an "isolated" nucleic acid is free of sequences that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid of interest).
[0067] The term "ka" refers to the constant for the rate of association of a given antibody-antigen interaction, while the term "kd" refers to the constant for the rate of dissociation of a given antibody-antigen interaction. antigen.
[0068] The term "KD" refers to the equilibrium dissociation constant of a given antibody-antigen interaction. It is obtained from the ratio of kd to ka (ie kd/ka) and is expressed in molar concentration (M). KD is used as a measure for the binding affinity of an antibody for its binding partner. The smaller the KD, the more tightly bound the antibody is or the higher the affinity between the antibody and the antigen. For example, an antibody with a nanomolar dissociation constant (nM) binds more tightly to a specific antigen than an antibody with a micromolar dissociation constant (μM). KD values for antibodies can be determined using methods well established in the art. One method of determining the KD of an antibody is by surface plasmon resonance, typically using a biosensor system such as the Biacore® system. A test procedure using the BIACORETM system (BIAcore test) is described in the Examples section of this patent application.
[0069] The term "mammal" refers to any animal species of the class Mammalia. Examples of mammals include: humans; laboratory animals such as rats, mice, apes and guinea pigs; domestic animals such as cats, dogs, rabbits, cattle, sheep, goats, horses and pigs; and wild animals in captivity such as lions, tigers, elephants and the like.
[0070] The term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, that is, the individual antibodies making up the population are identical, except for possible natural mutations that may be present in minimal amounts . Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, unlike polyclonal antibody preparations that include different antibodies directed against different determinants (epitopes), every monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they can be synthesized without being contaminated by other antibodies. The modifier "monoclonal" should not be interpreted as requiring production of the antibody by any particular method. For example, monoclonal antibodies can be prepared by hybridoma methodology or can be produced using recombinant DNA methods in bacterial, eukaryotic animal, or plant cells (see, for example, U.S. Patent No. 4,816,567). Monoclonal antibodies can also be isolated from phage-displayed antibody libraries using the techniques described in Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991), for example.
[0071] The term "preventing" or "preventing," with reference to a particular disease condition in a mammal, refers to preventing or delaying the onset of the disease or preventing the manifestation of its clinical or subclinical symptoms.
[0072] The term "recombinant antibody" refers to an antibody that is prepared, expressed, raised or isolated by recombinant means, such as antibodies isolated from an animal transgenic to immunoglobulin genes of another species, antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a combinatorial library of recombinant antibodies, or antibodies prepared, expressed, raised, or isolated by any other means that involve splicing immunoglobulin gene sequences and inserted into other gene sequences. DNA.
[0073] In this specification, "sequence identity" between two polypeptide sequences indicates the percentage of amino acids that are identical between the sequences. The identity of polypeptide amino acid sequences can be determined conventionally using known computer programs such as Bestfit, FASTA or BLAST (see, for example, Pearson, Methods Enzymol. 183:63-98 (1990); Pearson, Methods Mol. Biol 132:185-219 (2000); Altschul et al., J. Mol. Biol. 215:403-410 (1990); Altschul et al., Nucelic Acids Res. 25:3389-3402 (1997)). When using Bestfit or any other sequence alignment program to determine whether a given sequence is, for example, 95% identical to a reference amino acid sequence, the parameters are set such that percent identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed. This method cited above for determining percent identity between polypeptides can be applied to all proteins, fragments or variants thereof described in this patent application.
[0074] The term "specifically binds" or "specifically binds to", in reference to the interaction of a binding molecule, as defined in this specification, (for example, an antibody) with its binding partner (for example, an antigen) refers to the ability of the binding molecule to discriminate between an antigen of interest from one animal species and the ortholog of the antigen from a different animal species under a given set of conditions. A 4-1BB binding molecule is said to specifically bind human 4-1BB if it binds human 4-1BB at an EC50 that is below 50 percent of the EC50 to which it binds rat 4-1BB or mouse as determined in an in vitro assay. The binding specificity of an antibody can be determined by methods known in the art. Examples of such methods include FACS using primary cells stimulated with PHA, Western blot technique, ELISA tests, RIA, ECL, IRMA and peptide scans.
[0075] The term "selectively binds" or "selectively binds to", in reference to the interaction of a binding molecule, as defined in this specification, (eg, an antibody) with its binding partner (eg, an antigen), refers to the ability of the binding molecule to discriminate between an antigen of interest from an animal species (such as human 4-1BB) and a different antigen from the same animal species (such as human CD40) in a given set of conditions. A 4-1BB binding molecule is said to selectively bind to human 4-1BB if it binds to human 4-1BB at an EC50 that is below 10 percent of the EC50 at which it binds to human CD40 or CD134 human, as determined in an in vitro assay.
[0076] The term "treats", "treat" or "treatment", with reference to a particular disease condition in a mammal, refers to causing a desirable or beneficial effect on the mammal having the disease condition. The desirable or beneficial effect may include reduced frequency or severity of one or more symptoms of the disease (ie, tumor growth and/or metastasis or other effect mediated by numbers and/or activity of immune cells and the like) or interruption or inhibition further development of the disease, condition or disorder. In the context of treating cancer in a mammal, the desirable or beneficial effect may include inhibition of further growth or spread of cancer cells, death of cancer cells, inhibition of cancer relapse, reduction of pain associated with cancer, or improved survival of the mammal. The effect can be subjective or objective. For example, if the mammal is human, the human may notice improved vigor or vitality or diminished pain, as subjective symptoms of improvement or response to therapy. Alternatively, the physician may notice a decrease in tumor size or tumor burden on physical examination, laboratory parameters, tumor markers, or radiographic findings. Some laboratory signs that the doctor may look for a response to treatment include normalization of tests, such as white blood cell count, red cell count, platelet count, erythrocyte sedimentation rate, and levels of various enzymes. Additionally, the physician may observe a decrease in a detectable tumor marker. Alternatively, other tests can be used to assess objective improvement, such as sonograms, nuclear magnetic resonance tests, and positron emission tests.
The term "vector" refers to a nucleic acid molecule capable of transporting an exogenous nucleic acid molecule. The exogenous nucleic acid molecule is linked to the vector nucleic acid molecule by a recombinant technique, such as ligation or recombination. This allows the exogenous nucleic acid molecule to be multiplied, selected, further manipulated or expressed in a host cell or organism. A vector can be a plasmid, phage, transposon, cosmid, chromosome, virus or virion. One type of vector can be integrated into the genome of a host cell upon introduction into the host cell and thereby replicate along with the host genome (eg, non-episomal mammalian vectors). Another type of vector is capable of autonomous replication in a host cell into which they are introduced (eg, bacterial vectors having bacterial origin of replication and episomal mammalian vectors). Another specific type of vectors capable of directing the expression of exogenous expressible nucleic acids to which they are operably linked is commonly referred to as "expression vectors". Expression vectors generally have control sequences to direct the expression of exogenous expressible nucleic acids. Simpler vectors, known as "transcription vectors", are only capable of being transcribed, but not translated: these vectors can be replicated in a target cell, but not expressed. The term "vector" encompasses all types of vectors regardless of their function. Vectors capable of directing the expression of expressible nucleic acids to which they are operably linked are commonly referred to as "expression vectors".
[0078] The methods and techniques of the present invention are generally performed in accordance with methods well known in the art and as described in various general and more specific references which are cited and discussed throughout this specification, unless otherwise indicated. other way. Such references include, for example, Sambrook and Russell, Molecular Cloning, A Laboratory Approach, Cold Spring Harbor Press, Cold Spring Harbor, NY (2001), Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, NY ( 2002) and Harlow and Lane Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1990). The enzymatic reactions and purification techniques were carried out in accordance with the manufacturer's specifications, as performed in the technique or as described in this patent application. The related used nomenclatures and laboratory procedures and techniques of analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described in this patent application are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, for pharmaceutical preparation, formulation and release, and for the treatment of patients.
[0079] In this descriptive report, the twenty conventional amino acids and their abbreviations follow conventional usage. See Immunology--A Synthesis (2nd edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)). B. Binding molecules that bind to human 4-1bb
The present invention provides isolated binding molecules that bind to human 4-1BB, including antibodies to 4-1BB, antigen-binding fragments of antibodies to 4-1BB and derivatives of antibodies to 4-1BB. B-1. Antibodies against 4-1BB
In some aspects, the present invention provides an isolated antibody that binds to human 4-1BB at an epitope included within amino acid residues 115 - 156 of SEQ ID NO: 68. In some embodiments, the isolated antibody comprises the sequence the amino acid sequence of H-CDR1 of SEQ ID NO: 29, the amino acid sequence of H-CDR2 of SEQ ID NO: 30, and the amino acid sequence of H-CDR3 of SEQ ID NO: 31. In certain other embodiments, the antibody isolated comprises the L-CDR1 amino acid sequence of SEQ ID NO: 34, the L-CDR2 amino acid sequence of SEQ ID NO: 35 and the L-CDR3 amino acid sequence of SEQ ID NO: 36. embodiments, the antibodies described above possess one or more biological properties described below.
In other aspects, the invention provides an isolated antibody that binds to human 4-1BB, wherein said antibody comprises: (a) an H-CDR1 as shown in SEQ ID NO: 1, SEQ ID NO: 15 or SEQ ID NO: 29; (b) an H-CDR2 as set forth in SEQ ID NO: 2, SEQ ID NO: 16 or SEQ ID NO: 30; and (c) an H-CDR3 as set forth in SEQ ID NO: 3, SEQ ID NO: 17 or SEQ ID NO: 31.
[0083] In another aspect, the invention provides an isolated antibody that binds to human 4-1BB, wherein said antibody comprises: (a) an L-CDR1 as shown in SEQ ID NO:6, SEQ ID NO:20 or SEQ ID NO:34; (b) an L-CDR2 as set forth in SEQ ID NO:7, SEQ ID NO:21 or SEQ ID NO:35; and (c) an L-CDR3 as set forth in SEQ ID NO: 8, SEQ ID NO: 22, SEQ ID NO: 36 or SEQ ID NO: 55.
In a further aspect, the invention provides an isolated antibody which binds to human 4-1BB, wherein said antibody comprises: (a) an H-CDR1 as set forth in SEQ ID NO: 1, SEQ ID NO: 15 or SEQ ID NO: 29; (b) an H-CDR2 as set forth in SEQ ID NO: 2, SEQ ID NO: 16 or SEQ ID NO: 30; and (c) an H-CDR3 as set forth in SEQ ID NO: 3, SEQ ID NO: 17 or SEQ ID NO: 31; and further comprises: (d) an L-CDR1 as set forth in SEQ ID NO: 6, SEQ ID NO: 20 or SEQ ID NO: 34; (e) an L-CDR2 as set forth in SEQ ID NO:7, SEQ ID NO:21 or SEQ ID NO:35; and (f) an L-CDR3 as set forth in SEQ ID NO:8, SEQ ID NO:22, SEQ ID NO:36 or SEQ ID NO:55.
[0085] In some further aspects, the invention provides an isolated antibody that binds to human 4-1BB, wherein said antibody is selected from the group consisting of: (a) an antibody comprising an H-CDR1 as set forth in SEQ ID NO: 1, an H-CDR2 as shown in SEQ ID NO: 2 and an H-CDR3 as shown in SEQ ID NO: 3; (b) an antibody comprising an H-CDR1 as shown in SEQ ID NO: 15, an H-CDR2 as shown in SEQ ID NO: 16 and an H-CDR3 as shown in SEQ ID NO: 17; and (c) an antibody comprising an H-CDR1 as shown in SEQ ID NO: 29, an H-CDR2 as shown in SEQ ID NO: 30 and an H-CDR3 as shown in SEQ ID NO: 31.
[0086] In some further aspects, the invention provides an isolated antibody that binds to human 4-1BB, wherein said antibody is selected from the group consisting of: (a) an antibody comprising an L-CDR1 as set forth in SEQ ID NO: 6, an L-CDR2 as shown in SEQ ID NO: 7 and an L-CDR3 as shown in SEQ ID NO: 8; (b) an antibody comprising an L-CDR1 as shown in SEQ ID NO: 20, an L-CDR2 as shown in SEQ ID NO: 21 and an L-CDR3 as shown in SEQ ID NO: 22; (c) an antibody comprising an L-CDR1 as shown in SEQ ID NO: 34, an L-CDR2 as shown in SEQ ID NO: 35 and an L-CDR3 as shown in SEQ ID NO: 36; and (d) an antibody comprising an L-CDR1 as shown in SEQ ID NO: 34, an L-CDR2 as shown in SEQ ID NO: 35 and an L-CDR3 as shown in SEQ ID NO: 55.
[0087] In some further aspects, the invention provides an isolated antibody that binds to human 4-1BB, wherein said antibody is selected from the group consisting of: (a) an antibody comprising an H-CDR1 as set forth in SEQ ID NO: 1, an H-CDR2 as shown in SEQ ID NO: 2, an H-CDR3 as shown in SEQ ID NO: 3; an L-CDR1 as shown in SEQ ID NO: 6, an L-CDR2 as shown in SEQ ID NO: 7 and an L-CDR3 as shown in SEQ ID NO: 8; (b) an antibody comprising an H-CDR1 as shown in SEQ ID NO:15, an H-CDR2 as shown in SEQ ID NO:16, an H-CDR3 as shown in SEQ ID NO:17; an L-CDR1 as shown in SEQ ID NO: 20, an L-CDR2 as shown in SEQ ID NO: 21 and an L-CDR3 as shown in SEQ ID NO: 22; (c) an antibody comprising an H-CDR1 as shown in SEQ ID NO: 29, an H-CDR2 as shown in SEQ ID NO: 30, an H-CDR3 as shown in SEQ ID NO:31; an L-CDR1 as shown in SEQ ID NO: 34, an L-CDR2 as shown in SEQ ID NO: 35 and an L-CDR3 as shown in SEQ ID NO: 36; and (d) an antibody comprising an H-CDR1 as shown in SEQ ID NO:29, an H-CDR2 as shown in SEQ ID NO:30, an H-CDR3 as shown in SEQ ID NO:31; an L-CDR1 as shown in SEQ ID NO:34, an L-CDR2 as shown in SEQ ID NO:35 and an L-CDR3 as shown in SEQ ID NO:55.
[0088] In a further aspect, the invention provides an isolated antibody that binds to human 4-1BB, wherein said antibody comprises an amino acid sequence of VH in the chain as shown in SEQ ID NO:4, SEQ ID NO: 18, SEQ ID NO:32 or SEQ ID NO:43.
[0089] In a further aspect, the invention provides an isolated antibody that binds to human 4-1BB, wherein said antibody comprises an amino acid sequence of VL in the chain as shown in SEQ ID NO: 9, SEQ ID NO: 23, SEQ ID NO: 37, SEQ ID NO: 45, SEQ ID NO: 51, SEQ ID NO: 56, SEQ ID NO: 60 or SEQ ID NO: 64.
[0090] In a further aspect, the invention provides an isolated antibody that binds to human 4-1BB, wherein said antibody comprises (1) a VH amino acid sequence in the chain as shown in SEQ ID NO:4, SEQ ID NO: 18, SEQ ID NO: 32 or SEQ ID NO: 43 and (2) an amino acid sequence of VL in the chain as shown in SEQ ID NO: 9, SEQ ID NO: 23, SEQ ID NO: 37, SEQ ID NO: 45, SEQ ID NO: 51, SEQ ID NO: 56, SEQ ID NO: 60 or SEQ ID NO: 64.
[0091] In a further aspect, the invention provides an isolated antibody that binds to human 4-1BB, wherein said antibody is selected from the group consisting of: (a) an antibody comprising an amino acid sequence of VH in the chain as shown in SEQ ID NO: 4 and a VL amino acid sequence in the chain as shown in SEQ ID NO: 9; (b) an antibody comprising an in-chain VH amino acid sequence as shown in SEQ ID NO:18 and an in-chain VL amino acid sequence as shown in SEQ ID NO:23; (c) an antibody comprising an in-chain VH amino acid sequence as shown in SEQ ID NO: 32 and an in-chain VL amino acid sequence as shown in SEQ ID NO: 37 or SEQ ID NO: 56; and (d) an antibody comprising an in-chain VH amino acid sequence as shown in SEQ ID NO: 43 and an in-chain VL amino acid sequence as shown in SEQ ID NO: 45, SEQ ID NO: 51, SEQ ID NO. :60 or SEQ ID NO:64.
In some embodiments, antibodies described above, including antibodies described with reference to epitope binding and antibodies described with reference to specific amino acid sequences of CDRs or variable regions, possess at least one of the following functional properties: (a) bind to human 4-1BB with KD of 500 nM or less; (b) exhibit agonist activity on human 4-1BB; (c) do not bind to the human CD40 receptor at concentrations of up to 1000 nM; (d) do not bind to the human CD134 receptor at concentrations up to 1000 nM; (e) do not bind rat or mouse 4-1BB at concentrations up to 100 nM; (h) are capable of inhibiting tumor cell growth; and (i) have a therapeutic effect on cancer. In some additional embodiments, the antibodies specifically bind to human 4-1BB with KD of 500 nM or less, 100 nM or less, 50 nM or less, 10 nM or less, 5 nM or less, or 1 nM or less, to the extracellular domain of human 4-1BB, as measured with the BIACore assay described in this invention. In yet other embodiments, the antibody is a human antibody or humanized antibody that specifically binds to human 4-1BB with KD of 500 nM or less, 100 nM or less, 50 nM or less, 10 nM or less, 5 nM or less or 1 nM or less, for the 4-1BB extracellular domain, as measured with the BIACore assay described in this invention. In some additional embodiments, the antibody is a human antibody that specifically binds and selectively binds to human 4-1BB.
In other embodiments, the antibodies described above comprise a heavy chain variable region derived from a particular germline immunoglobulin heavy chain gene and/or a light chain variable region derived from a light chain gene of a germline immunoglobulin in particular, such as an antibody comprising the heavy chain variable region, which is the product or derivative of a human VH 1-69 gene, 3-23 VH gene or human VH 5 gene. Exemplary antibodies include MOR-7480.1, MOR-7480.2, MOR-7483.1 and MOR-7483.2, each of which contain amino acids that were derived from the human germline VH5 gene.
[0094] In yet other embodiments, the antibodies described above comprise a light chain variable region that is derived from a human VL Ã3 gene. In still other embodiments, the antibodies described above comprise a heavy chain variable region, which is the product or derived from a human VH 1-69 gene, VH 3-23 gene, or human VH 5 gene and further comprises a variable region a light chain that is the product or derivative of a human VL À3 gene, wherein the antibody or part thereof specifically binds to human 4-1BB. Exemplary antibodies include MOR-7480.1, MOR-7480.2, MOR-7483.1 and MOR-7483.2 each containing amino acids that were derived from the human germline VH5 gene and VL À3 gene, respectively.
[0095] In this specification, a human antibody comprises heavy or light chain variable regions that are "derived from" a given germline sequence if the antibody variable regions are obtained from a system using immunoglobulin genes of the human germline. Such systems include immunizing a transgenic mouse carrying human immunoglobulin genes with the antigen of interest or screening a phage-displayed human immunoglobulin gene library with the antigen of interest. A human antibody that is "derived from" a human germline immunoglobulin sequence can be identified as such by comparing the human antibody amino acid sequence to the human germline immunoglobulin amino acid sequences and selecting the sequence of human germline immunoglobulin that most closely resembles (i.e., with greater % identity) the sequence of the human antibody. A human antibody that is "derived from" a given human germline immunoglobulin sequence may contain amino acid differences compared to the germline sequence, which are due, for example, to natural somatic mutations or the intentional introduction of mutation site-directed. However, a selected human antibody is typically at least 90% identical in terms of amino acid sequence to an amino acid sequence encoded by a human germline immunoglobulin gene and contains amino acid residues that identify the human antibody as human when compared to the sequences of germline immunoglobulins from other species (eg, murine germline sequences). In certain instances, a human antibody may be at least 95% or even at least 96%, 97%, 98% or 99% identical in terms of amino acid sequence to the amino acid sequence encoded by the germline immunoglobulin gene. In certain cases, the human antibody is identical in terms of amino acid sequence to the amino acid sequence encoded by the germline Ig gene. Typically, a human antibody derived from a given human germline sequence will exhibit at most 10 amino acid differences from the amino acid sequence encoded by the human germline immunoglobulin gene. In certain cases, the human antibody may exhibit at most 5 or even at most 4, 3, 2 or 1 amino acid differences from the amino acid sequence encoded by the germline immunoglobulin gene. Alignments of the variable region amino acid sequences of the illustrative antibodies and the pertinent germlines are provided in Figure 6.
In another aspect, the invention provides isolated antibodies that compete or cross-compete for binding to human 4-1BB with any of the illustrative antibodies of the invention, such as MOR-6032, MOR-7361, MOR-7480, MOR -7480.1, MOR-7480.2, MOR-7483, MOR-7483.1 or MOR-7483.2. In a specific embodiment, the invention provides isolated antibodies that compete or cross-compete for binding to the same epitope on human 4-1BB with any of the illustrative antibodies of the invention. The ability of an antibody to cross-compete another antibody for binding can be determined using standard binding assays known in the art, such as BIAcore analysis, ELISA assays or flow cytometry. For example, an illustrative antibody of the invention can be allowed to bind to human 4-1BB under saturating conditions and then the ability of the antibody under test to bind to 4-1BB is measured. If the antibody under test is capable of binding 4-1BB at the same time as the illustrative antibody, then the antibody under test binds to a different epitope than the illustrative antibody. However, if the antibody under test is not able to bind to 4-1BB at the same time, the antibody under test then binds to the same epitope, an overlapping epitope, or an epitope in close proximity to the epitope bound by the illustrative antibody. This experiment can be performed using various methods such as ELISA, RIA, FACS or surface plasmon resonance.
The 4-1BB antibodies described herein may belong to any class, such as IgG, IgM, IgE, IgA or IgD. It is preferred that the antibodies against 4-1BB belong to the IgG class, such as the IgG1, IgG2, IgG3 or IgG4 subclasses, more preferably to the IgG2 subclass. A 4-1BB antibody can be converted from one class or subclass to another class or subclass using methods known in the art. An exemplary method for producing an antibody in a desired class or subclass comprises the steps of isolating a nucleic acid encoding a heavy chain of a 4-1BB antibody and a nucleic acid encoding a light chain of a 4-1BB antibody, isolating the sequence encoding the VH region, linking the VH sequence to a sequence encoding a heavy chain constant region of the desired class or subclass, expressing the light chain and heavy chain gene constructed in a cell, and collecting the antibody against 4-1BB.
[0098] Additionally, the antibodies provided by the present invention may be monoclonal or polyclonal, but preferably monoclonal.
[0099] Examples of specific isolated antibodies provided by the present invention include the following illustrative antibodies: MOR-6032, MOR-7361, MOR-7480, MOR-7480.1, MOR-7480.1, MOR-7480.2, MOR-7483, MOR-7483, MOR-7483.1 and MOR-7483.2. The nucleotide and amino acid sequences of the heavy chain variable region, the complete heavy chain for the IgG2 subclass, the light chain variable region, and the entire light chain of these antibodies are provided in this specification; an index of the SEQ ID NOs for these sequences is shown in Table 1. The amino acid sequences of the CDRs of these illustrative antibodies are shown in Table 2. Table: 1. Index of SEQ ID NOs
Table 2: CDR amino acid sequence


[00100] Antibodies of the present invention can be produced by techniques known in the art, including conventional methodology for monoclonal antibodies, e.g., the standard somatic cell hybridization technique (See, e.g., Kohler and Milstein, Nature 256:495 ( 1975)), viral or oncogenic B lymphocyte transformation or recombinant antibody technologies as described in detail below.
[00101] The production of hybridomas is a very well established procedure. The common animal system for preparing hybridomas is the murine system. Immunization protocols and techniques for isolating immunized splenocytes for fusion are known in the art. Fusion partners (eg murine myeloma cells) and procedures for fusion are also known. A well known method that can be used to produce the antibodies against human 4-1BB provided by the present invention involves the use of an animal XenoMouse™ system. The XenoMouseTM mice belong to constructed mouse strains that comprise large fragments of human immunoglobulin heavy chain and light chain locus and are deficient in mouse antibody production. See, for example, Green et al., Nature Genetics 7:13-21 (1994) and WO2003/040170. The animal is immunized with a 4-1BB antigen. The 4-1BB antigen is isolated and/or purified 4-1BB, preferably 4-1BB. This can be a fragment of 4-1BB, like the extracellular domain of 4-1BB, especially a fragment of the extracellular domain of 4-1BB comprising amino acid residues 115 - 156 of SEQ ID NO: 68. Immunization of animals can be performed by any method known in the art. See, for example, Harlow and Lane, Antibodies: A Laboratory Manual, New York: Cold Spring Harbor Press, 1990. Methods for immunizing non-human animals such as mice, rats, sheep, goats, pigs, cattle, and horses are well known in the art . See, for example, Harlow and Lane, supra, and U.S. Patent No. 5,994,619. The 4-1BB antigen can be administered with an adjuvant to stimulate the immune response. Exemplary adjuvants include Freund's complete or incomplete adjuvant, RIBI (muramyl dipeptides) or ISCOM (immunostimulating complexes). After immunizing an animal with a 4-1BB antigen, immortalized antibody-producing cell lines are prepared from cells isolated from the immunized animal. After immunization, the animal is sacrificed and lymph node or splenic B cells are immortalized. Methods to immortalize cells include, among others, the transfer of cells with oncogenes, their modulation with the oncogenic virus, and their cultivation under conditions in which immortalized cells are selected, subjecting them to carcinogenic or mutation-causing compounds, fusing the cells to a immortalized cell, eg a myeloma cell, and inactivating a tumor suppressor gene. See, for example, Harlow and Lane, supra. If fusion with myeloma cells is used, the myeloma cells preferably do not secrete immunoglobulin polypeptides (a non-secretory cell lineage). Immortalized cells are screened using 4-1BB, part of it or a cell expressing 4-1BB. Antibody producing cells against 4-1BB, e.g., hybridomas, are selected, cloned and further screened for desired characteristics, including robust growth, high antibody production, and desirable antibody characteristics, as discussed in more detail below. Hybridomas can be expanded in vivo in syngeneic animals, in animals lacking an immune system, for example, nude mice, or in in vitro cell culture. Methods for selecting, cloning and expanding hybridomas are well known to those skilled in the art.
Antibodies of the invention can also be prepared using phage display methods. Such phage display methods for isolating human antibodies are established in the art, such as the HuCAL® Libraries as described in more detail in Example 1. See also, for example: Achim Knappik, et al: Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides. J. Mol. Biol. (2000) 296, 5786. B-2. Antigen binding fragments
[00103] In some other aspects, the present invention provides antigen-binding fragments of any of the antibodies against 4-1BB provided by the present invention.
The antigen binding fragment may comprise any antibody sequences. In some embodiments, the antigen-binding fragment comprises the amino acid sequence of: (1) a light chain of an antibody against 4-1BB; (2) a heavy chain of an antibody against 4-1BB; (3) a variable region of the light chain of a 4-1BB antibody; (4) a heavy chain variable region of a 4-1BB antibody; (5) one or more CDRs (two, three, four, five or six CDRs) of an antibody against 4-1BB; or (6) three CDRs from the light chain and three CDRs from the heavy chain of an antibody against 4-1BB.
[00105] In some specific embodiments, the invention provides an antigen-binding fragment of an antibody selected from: MOR-6032, MOR-7361, MOR-7480, MOR-7480.1, MOR-7480.2, MOR-7483, MOR -7483.1 or MOR-7483.2.
[00106] In some other specific embodiments, the antigen-binding fragments of an antibody against 4-1BB include: (i) Fab fragment, which is a monovalent fragment formed by the VL, VH, CL and CH1 domains; (ii) F(ab')2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) Fd fragment consisting of VH and CH1 domains; (iv) Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; (vi) an isolated CDR and (vii) single chain antibody (scFv), which is a polypeptide comprising a VL region of an antibody linked to a VH region of an antibody. Bird et al., (1988) Science 242:423-426 and Huston et al., (1988) Proc. Natl. Academic Sci. USA 85:5879-5883.
[00107] In some specific embodiments, the antigen-binding fragment is a Fab fragment selected from the group consisting of Fab-6032, Fab-7361, Fab-7480 and Fab-7483. B.3. Antibody Derivatives
[00108] In some additional aspects, the present invention provides derivatives of any of the antibodies against 4-1BB provided by the present invention.
[00109] In one aspect, the antibody derivative is derived from modifications to the amino acid sequences of an illustrative antibody ("precursor antibody") of the invention while preserving the overall molecular structure of the precursor antibody amino acid sequence . Amino acid sequences from any regions of the precursor antibody can be modified, such as from framework regions, CDR regions or constant regions. Types of modifications include substitutions, insertions, deletions, or combinations thereof, of one or more amino acids of the precursor antibody. In some embodiments, the antibody derivative comprises a VH region that is at least 65%, at least 75%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least at least 98% or at least 99% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 4, 18, 32 or 43. In some other embodiments, the antibody derivative comprises a VL region that is at least 65 %, at least 75%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to an amino acid sequence as shown in any one of SEQ ID NOs: 9, 23, 37, 45, 51, 56, 60 or 64. In some specific embodiments, the derivative comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 , 11, 12, 13, 14 or 15 conservative or non-conservative substitutions and/or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 additions and/ or deletions to an amino acid sequence as shown in any one of SEQ ID NOs: 4, 18, 32, 43, 9, 23, 37, 45, 51, 56, 60 or 64.
[00110] Amino acid substitutions encompass conservative substitutions and non-conservative substitutions. The term "conservative amino acid substitution" means an exchange of one amino acid for another amino acid, where the two amino acids have similarity in certain chemical properties, such as polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues involved. . For example, substitutions can typically be made within each of the following groups: (a) non-polar (hydrophobic) amino acids such as alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine; (b) neutral polar amino acids such as glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine; (c) positively charged (basic) amino acids such as arginine, lysine and histidine; and (d) negatively charged (acidic) amino acids such as aspartic acid and glutamic acid.
[00111] Modifications can be made at any positions in the antibody's amino acid sequences, including the CDRs, framework regions or constant regions. In one embodiment, the present invention provides an antibody derivative that contains the VH and VL CDR sequences of an illustrative antibody of this invention, yet contains framework sequences different from those of the illustrative antibody. These framework sequences can be obtained from public DNA databases or from published references that include germline antibody gene sequences. For example, germline DNA sequences for human heavy and light chain variable region genes can be found in the Genbank database or in the "VBase" human germline sequence database (Kabat, EA, et al. , Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242 (1991); Tomlinson, IM, et al., J. Mol. Biol. 227:776- 798 (1992); and Cox, JPL et al., Eur. J. Immunol. 24:827-836 (1994)). Framework sequences that can be used to construct an antibody derivative include those that are structurally similar to the framework sequences used by the illustrative antibodies of the invention, for example, similar to the framework sequences VH 3-23 and/or framework sequences VL 3 or 1- 13 used by the illustrative antibodies of the invention. For example, the H-CDR1, H-CDR2 and H-CDR3 sequences and the L-CDR1, L-CDR2 and L-CDR3 sequences of an illustrative antibody can be grafted into framework regions that have the identical sequence as found in germline immunoglobulin gene from which the framework sequence is derived or the CDR sequences can be grafted into framework regions that contain one or more mutations as compared to the germline sequences.
[00112] In a specific embodiment, the antibody derivative is a chimeric antibody comprising an amino acid sequence of an illustrative antibody of the invention. In one example, one or more CDRs from one or more illustrative human antibodies are combined with CDRs from an antibody from a non-human animal, such as a mouse or rat. In another example, all of the chimeric antibody CDRs are derived from one or more illustrative antibodies. In some specific embodiments, the chimeric antibody comprises one, two or three CDRs from the heavy chain variable region or light chain variable region of an illustrative antibody. Chimeric antibodies can be generated by conventional methods well known in the art.
[00113] Another type of modification is to cause the mutation of amino acid residues within the CDR1, CDR2 and/or CDR3 regions of the VH and/or VL chain. Site-directed mutagenesis or PCR-mediated mutagenesis can be performed to introduce the mutation(s), and the effect on antibody binding or other functional property of interest can be evaluated in in vitro or in vivo assays known in the art . Typically, conservative substitutions are introduced. Mutations can be amino acid additions and/or deletions. Furthermore, typically no more than one, two, three, four or five residues within a CDR region are changed. In some embodiments, the antibody derivative comprises 1, 2, 3 or 4 amino acid substitutions in the light chain H-CDRs and/or CDRs. In another embodiment, the amino acid substitution is replacing one or more cysteines in an antibody with another residue, such as, but not limited to, alanine or serine. Cysteine can be a canonical or non-canonical cysteine. In one embodiment, the antibody derivative has 1, 2, 3 or 4 conservative amino acid substitutions in the H-CDR regions relative to the amino acid sequences of an illustrative antibody.
[00114] Modifications can also be made to framework residues (framework) within the VH and/or VL regions. Typically, such framework variants are intended to decrease the immunogenicity of the antibody. A "reverse mutation" approach at one or more framework residues to the corresponding germline sequence. An antibody that has undergone a somatic mutation may contain framework residues that differ from the germline sequence from which the antibody is derived. Such residues can be identified by comparing the antibody framework sequences to the germline sequences from which the antibody is derived. In order for framework region sequences to return to their germline configuration, somatic mutations can be "back mutated" to the germline sequence, for example, by site-directed mutagenesis or by PCR-mediated mutagenesis. Several of the illustrative antibodies of the present invention have undergone such "reverse mutations" to certain germline sequences, as described in detail in Example 6.
In addition, modifications may also be made within the Fc region of an illustrative antibody, typically to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and/or antigen-dependent cellular cytotoxicity. In one example, the hinge region of CH1 is modified in such a way that the number of cysteine residues is changed, for example, increased or decreased. This approach is described in more detail in U.S. Patent No. 5,677,425. The number of cysteine residues on the hinge region of CH1 is altered, for example, to facilitate light and heavy chain assembly or to increase or decrease antibody stability. In another case, the Fc ring region of an antibody is mutated to shorten the biological half-life of the antibody.
[00116] Furthermore, an antibody of the invention can be modified to alter its site or potential pattern of glycosylation. Illustrative antibodies MOR-7480 and MOR-7483, and any variants of their germlines and antibodies that comprise the heavy chain variable region amino acid sequences of MOR-7480 and MOR-7483, comprise a potential N-linked glycosylation site ( NYS) in asparagine 59 of the heavy chain variable domain. IgG versions of these antibodies further comprise a second N-linked glycosylation site in the Fc domain of the heavy chain. More specifically, for the IgG2 version of these antibodies, the Fc-N-linked glycosylation site (NST) occurs in the asparagine 292 of the heavy chain CH2 domain. Thus, each heavy chain can comprise 0, 1 (in Fab or Fc) or 2 glycan occupations such that an antibody comprising two heavy chains and two light chains can comprise any combination ranging from 0 glycan occupation (i.e., no glycosylation at any of the four possible glycosylation sites) to 4 glycan occupations (ie, glycosylated at the Fab and Fc sites in each chain). In another aspect, the present invention provides a derivative of a 4-1BB antibody of the invention which contains at least one mutation in a light chain or heavy chain variable region which alters the glycosylation pattern in the variable region. Such an antibody derivative may exhibit increased affinity and/or modified specificity by binding to an antigen. Mutations can add a new glycosylation site in the V region, alter the location of one or more glycosylation sites in the V region, or remove a pre-existing glycosylation site in the V region. In one embodiment, the present invention provides a derivative of an antibody against 4-1BB having a potential N-linked glycosylation site in asparagine 59 of the heavy chain variable region, wherein the potential N-linked glycosylation site in a heavy chain variable region is removed. In another embodiment, the present invention provides a derivative of an antibody against 4-1BB having a potential N-linked glycosylation site in asparagine 59 of the heavy chain variable region, wherein the potential N-linked glycosylation site in both regions heavy chain variables is removed. Methods of altering the glycosylation pattern of an antibody are known in the art, such as those described in U.S. Patent No. 6,933,368, the contents of which are incorporated herein by reference in this patent application.
[00117] In another aspect, the present invention provides an antibody derivative comprising a 4-1BB antibody or antigen-binding fragment thereof, as described herein, linked to an additional molecular entity. Examples of additional molecular entities include pharmaceutical agents, peptides or proteins, detection agent or labels, and antibodies.
In some embodiments, the antibody derivative comprises an antibody of the invention linked to a pharmaceutical agent. Examples of pharmaceutical agents include cytotoxic agents or other therapeutic agents for cancer and radioactive isotopes. Specific examples of cytotoxic agents include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracine dione, mitoxantrone, mitramycin, actinomycin , glucocorticoids, procaine, tetracaine, lidocaine, propranolol and puromycin and analogues or homologues thereof. Therapeutic agents can also include, for example, antimetabolites (for example, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (for example, mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (eg, daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (eg, dactinomycin (formerly actinomycin), bleomycin, mithramycin and anthramycin (AMC)) and antimitotic agents (eg, vincristine and vinblastine). Examples of radioactive isotopes that can be conjugated to antibiotics for diagnostic or therapeutic use include, among others, iodine131, indium111, yttrium90, and lutetium177. Methods of linking an antibody to a pharmaceutical agent are known in the art, such as using various linker technologies. Examples of types of linker include hydrazones, thioethers, esters, disulfides and peptide-containing linkers. For a more detailed discussion of linkers and methods of attaching therapeutic agents to antibody, see also Saito et al., Adv. Drug Deliv. Rev. 55:199-215 (2003); Trail, et al., Cancer Immunol. Immunother. 52:328-337 (2003); Payne, Cancer Cell 3:207212 (2003); Allen, Nat. Rev. Cancer 2:750-763 (2002); Pastan, I. and Kreitman, Curr. Opinion Investigation Drugs 3:1089-1091 (2002); Senter, P.D. and Springer, C.J. (2001) Adv. Drug Deliv. Rev. 53:247-264.
[00119] In a specific embodiment, the antibody derivative is a 4-1BB antibody multimer, which is a multimeric form of a 4-1BB antibody, such as dimers, trimers or higher order multimers of monomeric antibodies . The individual monomers within an antibody multimer can be identical or different. Additionally, individual antibodies within a multimer can have the same or different binding specificities. Antibody multimerization can be accomplished through natural antibody aggregation. For example, some percentage of purified antibody preparations (eg, purified IgG1 molecules) spontaneously form protein aggregates containing antibody homodimers and other higher-order antibody multimers. Alternatively, antibody homodimers can be formed by chemical linkage techniques known in the art, such as via crosslinking agents. Suitable crosslinkers include heterobifunctional ones, which have two distinctly reactive groups separated by an appropriate spacer (such as m-maleimidobenzoyl-N-hydroxysuccinimide ester, succinimidyl 4-(maleimidomethyl)cyclohexane-1-carboxylate, and N-succinimidyl S-acetylthio-acetate , or homobifunctionals (such as disuccinimidyl suberate). Such linkers are commercially available from, for example, Pierce Chemical Company, Rockford, IL. Antibodies can also be induced to multimerize by recombinant DNA techniques known in the art.
[00120] Examples of other antibody derivatives provided by the present invention include single chain antibodies, diabodies, domain antibodies, nanobodies and unibodies. A "single-chain antibody" (scFv) is comprised of a single polypeptide chain comprising a VL domain linked to a VH domain, wherein the VL domain and the VH domain are paired and form a monovalent molecule. The single chain antibody can be prepared according to a method known in the art (see, for example, Bird et al., (1988) Science 242:423-426 and Huston et al., (1988) Proc. Natl. Acad Sci. USA 85:5879-5883). A "diabody" is made up of two chains, each chain comprising a heavy chain variable region connected to a light chain variable region on the same polypeptide chain connected by a short linker peptide, where the two regions on the same chain do not pair with each other. , but with complementary domains on the other chain and form a bispecific molecule. Methods for preparing diabodies are known in the art (See, for example, Holliger P. et al., (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448 and Poljak RJ et al., (1994) Structure 2 :1121-1123). Domain antibodies (dAbs) are small functional antibody binding units, corresponding to the variable regions of antibody heavy or light chains. Domain antibodies are well expressed in bacterial, yeast and mammalian cell systems. Additional details on domain antibodies and methods for their production are known in the art (see, for example, US Patent Nos. 6,291,158; 6,582,915; 6,593,081; 6,172,197; 6,696,245; European Patents 0368684 and 0616640; WO05/035572, WO04/101790, WO04/081026, WO04/058821, WO04/003019 and WO03/002609). Nanobodies are derived from the heavy chains of an antibody. A nanobody typically comprises a single variable domain and two constant domains (CH2 and CH3) and retains the antigen-binding capacity of the original antibody. Nanobodies can be prepared by methods known in the art (See, for example, U.S. Patent No. 6,765,087, U.S. Patent No. 6,838,254, WO 06/079372). Unibodies consist of a light chain and a heavy chain of an IgG4 antibody. Unibodies can be produced by removing IgG4 antibodies from the hinge region. Further details on unibodies and methods for their preparation can be found in WO2007/059782. C. Nucleic Acids, Vectors, Host Cells, and Recombinant Methods for Making Antibodies to 4-1BB
Another aspect of the invention provides an isolated nucleic acid molecule which comprises a nucleotide sequence encoding an amino acid sequence of a binding molecule provided by the present invention. The amino acid sequence encoded by the nucleotide sequence can be any part of an antibody, such as a CDR, a sequence comprising one, two or three CDRs, a variable region of a heavy chain, a variable region of a light chain, or can be a complete heavy chain or a complete light chain. A nucleic acid of the invention can be, for example, DNA or RNA and may or may not contain intronic sequences. Typically, the nucleic acid is a cDNA molecule.
[00122] In some embodiments, the invention provides an isolated nucleic acid molecule that comprises or consists of a nucleotide sequence encoding an amino acid sequence selected from the group consisting of: (1) amino acid sequence of H-CDR3 or L-CRD3 of an illustrative antibody; (2) variable region of a heavy chain or variable region of a light chain of an illustrative antibody; or (3) complete heavy chain or complete light chain of an illustrative antibody.
In other embodiments, the nucleic acid molecule comprises or consists of a nucleotide sequence that encodes an amino acid sequence as shown in any one of SEQ ID NOs: 1 - 10, 15-24, 29 - 38, 43, 44, 45, 46, 51.52, 5557, 60, 61, 64 and 65.
[00124] In still other embodiments, the nucleic acid molecule comprises or consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 11-14, 2528, 39-42, 47-50, 53, 54, 58, 59, 62, 63, 66 and 67.
[00125] Nucleic acids of the invention can be obtained by any suitable technique of molecular biology. For antibodies expressed by hybridomas, cDNAs encoding the light and heavy chains of the antibody produced by the hybridoma can be obtained by PCR amplification or cDNA cloning techniques. For antibodies obtained from an immunoglobulin gene library (for example, using phage display techniques), nucleic acid encoding the antibody can be recovered from the library.
The isolated DNA encoding the VH region can be converted into a complete heavy chain gene by operatively linking the DNA encoding the VH to another DNA molecule encoding heavy chain constant regions (CH1, CH2 and CH3). Human heavy chain constant region gene sequences are known in the art (see, for example, Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, United States Department of Health and Human Services, Publication NIH No. 91-3242) and DNA fragments spanning these regions can be obtained by standard PCR amplification. The heavy chain constant region can be an IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD constant region, however, most preferable is an IgG1 or IgG4 constant region. The IgG1 constant region sequence can be any one of several alleles or allotypes known to occur between different individuals, such as Gm(1), Gm(2), Gm(3) and Gm(17). These allotypes represent a natural amino acid substitution in the constant regions of IgG1. For a Fab fragment heavy chain gene, the VH encoding DNA can be operably linked to another DNA molecule encoding only the heavy chain CH1 constant region.
[00127] Isolated DNA encoding the VL region can be converted into a complete light chain gene (as well as a Fab light chain gene), operatively linking the VL encoding DNA to another DNA molecule encoding the constant region of the light chain, CL. Human light chain constant region gene sequences are known in the art (see, for example, Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, United States Department of Health and Human Services, Publication NIH No. 91-3242) and DNA fragments spanning these regions can be obtained by standard PCR amplification. The light chain constant region can be either a kappa or a lambda constant region.
[00128] To create an scFv gene, the DNA fragments encoding VH and VL are operably linked to another fragment encoding a flexible linker, for example, encoding the amino acid sequence (Gly4 -Ser)3 in such a way that the VH and VL sequences can be expressed in a contiguous single-chain protein, with the VL and VH regions joined by the flexible linker (see, for example, Bird et al., Science 242:423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and McCafferty et al., Nature 348:552-554 (1990)).
The present invention further provides a vector comprising a nucleic acid molecule provided by the present invention. The nucleic acid molecule can encode a part of a light chain or heavy chain (such as a CDR or a variable region), a complete light or heavy chain, a polypeptide comprising part of either the heavy or light chain, or an amino acid sequence of derivative antibody or antigen-binding fragment. In some embodiments, the vector is an expression vector useful for expressing a binding molecule, such as an antibody or antigen-binding fragment thereof.
[00130] In order to express a binding molecule of the invention, DNAs encoding partial or complete light and heavy chains are inserted into expression vectors in such a way that the DNA molecules are operably linked to transcriptional and translational control sequences. In this context, the term "operatively linked" means that an antibody gene is linked to a vector in such a way that transcriptional and translational control sequences within the vector act in their intended function of regulating the transcription and translation of the DNA molecule. . The expression vector and expression control sequences are chosen to be compatible with the host cell used for expression. The antibody light chain gene and the antibody heavy chain gene can be inserted as a separate vector or, more typically, both genes are inserted into the same expression vector. Antibody genes are inserted into the expression vector by any suitable methods (eg ligation of complementary restriction sites in the antibody gene fragment and in the vector or ligation at blunt ends if no restriction sites are present). The light and heavy chain variable regions of the antibodies described herein can be used to create complete antibody genes of any antibody isotype and subclass by inserting them into expression vectors that already encode the heavy and light chain constant regions of the antibody. isotype and desired subclass, such that the VH segment is operatively linked to the CH segment(s) within the vector and the VK segment is operatively linked to the CL segment within the vector. Additionally or alternatively, the recombinant expression vector can encode a signal peptide that facilitates secretion of the antibody chain from a host cell. The antibody chain gene can be cloned into the vector such that the signal peptide is linked in frame (in reading frame) to the amino terminus of the antibody chain gene. The signal peptide can be an immunoglobulin signal peptide or a heterologous signal peptide (that is, a signal peptide from a protein other than immunoglobulin).
[00131] In addition to the antibody chain genes, the expression vectors of the invention typically carry regulatory sequences that control the expression of the antibody chain genes in a host cell. The term "regulatory sequence" is intended to include promoters, enhancers, and other expression control elements (e.g., polyadenylation signals) that control the transcription or translation of antibody chain genes. These regulatory sequences are described, for example, in Goeddel (Gene Expression Technology. Methods in Enzymology 185, Academic Press, San Diego, CA (1990)). It will be recognized by those skilled in the art that the design of the expression vector, including the selection of regulatory sequences, may depend on such factors as the choice of host cell to be transformed, the desired level of protein expression, etc. Examples of regulatory sequences for expression in mammalian host cell include viral elements that drive high levels of protein expression, such as promoters and/or enhancers derived from cytomegalovirus (CMV), Simian Virus 40 (SV40), adenovirus, (e.g. , the adenovirus major late promoter (AdMLP)) and polyoma. Alternatively, non-viral regulatory sequences can be used, such as the ubiquitin promoter or the β-globin promoter. In addition, regulatory elements composed of sequences from different sources, such as the SR promoter system, which contains sequences from the SV40 early promoter and the human leukemia virus type 1 T-cell long repeat terminus (Takebe, Y. et al. (1988) Mol. Cell. Biol. 8:466-472).
[00132] In addition to antibody chain genes and regulatory sequences, expression vectors may carry additional sequences, such as sequences that regulate vector replication in host cells (eg origins of replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see, for example, U.S. Patent Nos. 4,399,216, 4,634,665, and 5,179,017, all issued to Axel et al.). For example, typically, the selectable marker gene confers resistance to drugs, such as G418, hygromycin, or methotrexate, to a host cell into which the vector was introduced. Selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in dhfr- host cells with methotrexate selection/amplification) and the neo gene (for G418) selection.
[00133] For the expression of the light and heavy chains, the expression vector(s) encoding the heavy and light chains is (are) transfected into a host cell by any suitable techniques. The various forms of the term "transfection" are intended to encompass a wide variety of techniques commonly used for introducing exogenous DNA into a prokaryotic or eukaryotic host cell, eg electroporation, calcium phosphate precipitation, DEAE-dextran transfection and the like. While it is possible to express the antibodies of the invention in prokaryotic and eukaryotic host cells, expression of antibodies in eukaryotic cells and typically mammalian host cells is more typical.
The present invention further provides a host cell containing a binding molecule provided by the present invention. The host cell can be virtually any cell for which expression vectors are available. It can be, for example, a higher class eukaryotic host cell, such as a mammalian cell, a lower class eukaryotic host cell, such as a yeast cell, and it can be a prokaryotic cell, such as a bacterial cell. Introduction of the engineered recombinant nucleic acid into the host cell can be effected by calcium phosphate transfection, DEAE, dextran mediated transfection, electroporation or phage infection.
Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and several species within the Pseudomonas, Streptomyces and Staphylococcus genera.
Mammalian host cells for the expression of a binding molecule of the invention include, for example, Chinese Hamster Ovary (CHO) cells (including CHO dhfr- cells, described in Urlaub and Chasin, Proc. Natl. Acad. Sci. USA 77:4216-4220 (1980)), used with a DHFR selectable marker, for example, as described in Kaufman and Sharp, J. Mol. Biol. 159:601621 (1982), myeloma NS0 cells, COS cells and Sp2 cells. In particular, for use with NS0 myeloma or CHO cells, another expression system is the GS (glutamine synthetase) gene expression system disclosed in WO 87/04462, WO 89/01036 and EP 338,841. When expression vectors encoding antibody genes are introduced into mammalian host cells, the antibodies are produced by culturing the host cells for a period of time sufficient to allow expression of the antibody in the host cells or secretion of the antibody in the culture medium in which host cells are cultured. Antibodies can be recovered from the culture medium using any suitable protein purification methods. D. Compositions
[00137] In other aspects, the present invention provides a composition containing a binding molecule provided by the invention. In one aspect, the composition is a pharmaceutical composition including a binding molecule and a pharmaceutically acceptable carrier. Compositions can be prepared by conventional methods known in the art.
The terms "pharmaceutical composition" and "pharmaceutical formulation" refer to compositions including any of the binding molecules, any of the antibodies, any of its antigen-binding parts as described herein, together with one or plus pharmaceutically acceptable excipients, diluents or carriers as needed to prepare the dosage forms for the effective release of the binding molecule.
In some embodiments, the present invention provides a composition including an antibody or antigen-binding portion thereof, provided by the present invention, and a pharmaceutically acceptable carrier, wherein said antibody or antigen-binding portion comprises a variable domain containing the CDR amino acid sequence shown in SEQ ID NO: 30 and wherein said composition does not include more than approximately 11%, 10%, 8%, 5%, 3% or 2% of said antibody or binding moiety the antigen that is glycosylated on the asparagine of said amino acid sequence, as compared to the total amount of antibody or its antigen-binding part, present in said composition. In another embodiment, the composition includes at least approximately 2% of said antibody or antigen-binding portion, which is glycosylated to the asparagine of said amino acid sequence of SEQ ID NO: 30, as compared to the total amount of antibody or its antigen-binding part, present in said composition.
[00140] In this specification, the term "excipient" means the substances used to formulate the active pharmaceutical ingredients in pharmaceutical formulations; in a preferred embodiment, an excipient does not reduce or interfere with the primary therapeutic effect of the active pharmaceutical ingredients. Preferably, an excipient is therapeutically inert. The term "excipient" encompasses carriers, diluents, vehicles, solubilizers, stabilizers, bulking agents, acidic or basic pH adjusting agents, and binders. Excipients can also be those substances present in a pharmaceutical formulation as an indirect or unintended result of the manufacturing process. Preferably, excipients are approved or considered to be safe for human and animal administration, ie GRAS substances (generally considered to be safe). GRAS substances are listed by the Food and Drug administration in the Code of Federal Standards (CFR) at 21 CFR 182 and 21 CFR 184, incorporated herein by reference in this application.
[00141] The term "pharmaceutically acceptable carrier" refers to any inactive substance that is suitable for use in a formulation for the release of a binding molecule. A carrier can be a non-stick, binder, coating, filler or diluent, preservative (such as an antioxidant, antibacterial or antifungal agent), sweetener, absorption delaying agent, wetting agent, emulsifying agent, buffer and the like. Examples of suitable pharmaceutically acceptable carriers include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), dextrose, vegetable oils (such as olive oil), saline, buffer, buffered saline and isotonic agents with sugars, polyalcohols , sorbitol and sodium chloride.
The term "buffering agent" refers to a pharmaceutically acceptable excipient that stabilizes the pH of a pharmaceutical preparation. Suitable buffers are well known in the art and can be found in the literature. For example, histidine buffers, glycine buffers, tris or acetate buffers and/or their respective free acids or bases, as well as mixtures of the various salts and/or acids and bases thereof can be employed. In a specific embodiment, the buffers are histidine buffers, that is, buffers having histidine, usually L-histidine, as a buffering agent. One particular buffer is L-histidine/HCl buffer, comprising L-histidine, L-histidine monohydrochloride or mixtures of L-histidine and L-histidine monohydrochloride. L-histidine buffers are generally used at a concentration of approximately 0.05 mg/ml to approximately 10 mg/ml, approximately 0.1 mg/ml to approximately 5 mg/ml or approximately 0.5 mg/ml at approximately 1 mg/ml. L-histidine monohydrochloride buffers are generally used at a concentration of approximately 0.1 mg/ml to approximately 10 mg/ml, from approximately 1 mg/ml to approximately 5 mg/ml or from approximately 2 mg/ml to approximately 4 mg/ml.
[00143] Regardless of the buffer used, the pH can be adjusted to a value in the range of approximately 4.0 to approximately 7.0 or from approximately 5.0 to approximately 6.0 with an acid or base known in the art, by example, hydrochloric acid, acetic acid, phosphoric acid, sulfuric acid and citric acid, sodium hydroxide and potassium hydroxide.
In one aspect, the present invention relates to a pharmaceutical composition comprising: 0.1 to 1 mg/ml of L-Histidine; 1 to 5 mg/ml L-Histidine monohydrochloride; 50 to 100 mg/ml dehydrated Trehalose; 0.01 to 0.1 mg/ml EDTA Disodium dihydrate; and 0.05 to 1 mg/ml of polysorbate 80; at pH in the range of 4.0 to 7.0.
[00145] In a specific embodiment, the concentration of the binding molecule included in the composition according to the invention is in the range of approximately 10 to approximately 22 mg/ml.
[00146] In another specific embodiment, the buffering agent included in the composition according to the invention is a histidine buffer, for example L-histidine/HCl buffer or acetate buffer or sodium acetate buffer. In a specific embodiment, the buffering agent is L-histidine/HCl.
In a specific embodiment, the buffer is at a concentration of approximately 0.1 mM to approximately 50 mM or approximately 1 mM to approximately 25 mM.
[00148] The pH of a composition of the invention can be chosen from the following ranges: from 3 to 10 or from 4 to 9. In a specific modality, the buffering agent provides pH from 5.0 to 6.0 or 5 .5 ± 0.3. Routine pH adjustments within and outside these ranges may be necessary to improve the solubility or stability of the polypeptide or other components of the composition.
[00149] In one embodiment, the composition includes a polysorbate, for example, polysorbate 20 or polysorbate 80. In a specific embodiment, polysorbate 80 is at a concentration of 0.01 to 10 mg/ml, 0.5 to 5 mg/ml or from 0.1 to 0.5 mg/ml.
[00150] In one embodiment, at least one stabilizer included in the composition according to the invention is selected from the group of salts, for example, sodium chloride, saccharides, trehalose dihydrate or sucrose and amino acids such as arginine hydrochloride. In a specific modality, one less stabilizer is at a concentration of 10 to 200 mg/ml, 20 to 150 mg/ml or 50 to 100 mg/ml.
[00151] In this specification, the term "chelating agent" generally refers to an excipient that is capable of forming at least one bond (eg, covalent, ionic or otherwise) with a metal ion. A chelating agent is typically a multi-tooth binder that can be used in selected liquid compositions as a stabilizer to form complexes with species that could promote instability. Often, compounds that can act as a chelating agent will have electron-rich functional groups. Suitable electron-rich functional groups include carboxylic acid groups, hydroxy groups and amino groups. The arrangement of these groups into aminopolycarboxylic acids, hydroxypolycarboxylic acids, hydroxyaminocarboxylic acids and the like results in groups that have the ability to bind metal.
[00152] However, the present invention is not intended to be limited to chelating agents that enhance the stability of the antibody primarily by the ability of the chelating agent to form bonds with a metal ion. Therefore, the present invention is not intended to be limited by the specific mechanism by which the chelating agent stabilizes the compositions of the present invention, and excipients called chelating agents in this specification can achieve their antibody stability enhancing properties primarily through mechanisms which are absolutely not related to the ability of the chelating agent to form bonds with a metal ion.
[00153] Chelating agents that are suitable for use in the present invention include, among others, aminopolycarboxylic acids, hydroxyaminocarboxylic acids, N-substituted glycines, 2-(2-amino-2-oxoethyl) aminoethane sulfonic acid (BES), deferoxamine (DEF ), citric acid, niacinamide and deoxycholates. Examples of suitable aminopolycarboxylic acids include ethylenediaminetetraacetic acid (EDTA), diethylenetriamianopentacetic acid (DTPA), nitrilotriacetic acid (NTA), N-2-acetamido-2-iminodiacetic acid (ADA), bis(aminoethyl)glycoether, N,N acid, N',N'-tetraacetic(EGTA), trans-diaminocyclohexane tetraacetic acid (DCTA), glutamic acid and aspartic acid. Examples of suitable hydroxyaminocarboxylic acids include N-hydroxyethyliminodiacetic acid (HIMDA), N,N-bis-hydroxyethylglycine (bicine) and N-(tris-hydroxymethylmethyl) glycine (tricine). An example of a suitable N-substituted glycine is glycylglycine. An example of a suitable deoxycholate is sodium deoxycholate.
Chelating agents used in the invention may be present, where possible, in the free acid or free base form of the compound (for example, referred to alternately herein as "EDTA" or "edetate") or in the form of a corresponding salt ( for example the corresponding acid addition or basic addition salt such as disodium edetate). Suitable acid addition salts include, for example, alkali metal salts (eg sodium or potassium salts), alkaline earth metal salts (eg calcium) and salts may be prepared using other loosely bound metal ions. . As known in the art, the nature of the salt and the number of charges to be neutralized will depend on the number of carboxyl groups present and the pH at which the stabilizing chelating agent is supplied. As is also known in the art, chelating agents have varying strengths with which particular target ions are bound. By way of further illustration, suitable salts of EDTA include dipotassium edetate, disodium calcium edetate, sodium edetate, trisodium edetate and potassium edetate; and a suitable salt of deferoxamine (DEF) is deferoxamine mesylate (DFM).
Chelating agents used in the invention may be present in anhydrous, solvated or hydrated form of the compound or the corresponding salt. When in solvated or hydrated form, the chelating agent can be present in varying states of solvation or hydration (including, for example, anhydrous, hydrated, dihydrated and trihydrated forms). By way of further illustration, a suitable hydrate of EDTA is disodium EDTA dihydrate. In one embodiment, disodium EDTA dihydrate is at a concentration of 0.001 to 5 mg/mL, 0.01 to 2 mg/mL, and 0.02 to 0.5 mg/mL. In another embodiment, the chelating agent can reduce or prevent aggregation of antibodies in the compositions described herein. These chelating agents can reduce or prevent degradation of an antibody that is formulated without the protection of a chelating agent.
[00156] Pharmaceutical compositions can in general be tailored to the specific intended route of administration. There are multiple techniques for administering a compound in the art, including but not limited to oral, aerosol, parenteral and topical administration. The compositions may be in any suitable form, such as liquid, semi-solid and solid dosage forms. Examples of liquid dosage forms include solution (eg, injectable and infusion solutions), microemulsion, liposome, dispersion or suspension. Examples of solid dosage forms include tablet, pill, capsule, microcapsule and powder. A particular form of composition suitable for releasing a binding molecule is a sterile liquid, in solution, suspension or dispersion, for injection or infusion. Sterile solutions can be prepared by incorporating the antibody in the desired amount in an appropriate vehicle, followed by microfiltration and sterilization. In general, dispersions are prepared by incorporating the antibody into a sterile vehicle which contains a basic dispersion medium and other carriers. In the case of sterile powder for the preparation of sterile liquid, preparation methods include vacuum drying and freeze-drying (lyophilization) to produce a powder of the active ingredient plus any additional desired ingredient from a sterile, previously filtered solution of the active ingredient. The various dosage forms of the compositions can be prepared by conventional techniques known in the art.
[00157] The relative amount of a binding molecule included in the composition will vary depending on a few factors, such as the binding molecule and specifically used vehicles, the dosage form and the desired release and pharmacodynamic characteristics. In one embodiment, the composition comprises a binding molecule, wherein the concentration of said binding molecule is between 1 and 100 mg/ml, between 5 and 50 mg/ml, or between 10 and 22 mg/ml. The amount of a binding molecule in a single dosage form will generally be that amount that produces a therapeutic effect, but it may also be a smaller amount. In general, this amount will range from approximately 0.1 percent to approximately 70 percent or from approximately 1 percent to approximately 30 percent based on the total weight of the dosage form.
[00158] In addition to the binding molecule, one or more additional therapeutic agents may be included in the composition. Examples of additional therapeutic agents are described below. The appropriate amount of additional therapeutic agent to be included in the composition can readily be selected by one of ordinary skill in the art and will vary depending on such factors as the particular agent and vehicles used, the dosage form, and the desired release and pharmacodynamic characteristics . The amount of additional therapeutic agent included in an isolated dosage form will generally be that amount which produces a therapeutic effect, but may also be a smaller amount. E. Use of binding molecules and pharmaceutical compositions
[00159] The binding molecules and pharmaceutical compositions provided by the present invention are useful for therapeutic, diagnostic or other purposes, such as enhancing an immune response, treating cancer, enhancing the effectiveness of other cancer therapy, enhancing the effectiveness of vaccines or treat autoimmune diseases. Therefore, in other aspects, the present invention provides methods of using binding molecules or pharmaceutical compositions. In one aspect, the present invention provides a method of treating a disorder in a mammal, which comprises administering to the mammal in need of treatment a therapeutically effective amount of a binding molecule provided by the invention. The binding molecule is a 4-1BB agonist or antagonist. In some embodiments, the binding molecule is a 4-1BB agonist. In some embodiments, the mammal is a human.
[00160] In some modalities, the disorder is cancer. A variety of cancers in which 4-1BB is involved, whether malignant or benign and whether primary or secondary, can be treated or prevented with a method provided by the invention. Examples of such cancers include lung cancers such as bronchogenic carcinoma (eg, squamous cell carcinoma, small cell carcinoma, large cell carcinoma and adenocarcinoma), alveolar cell carcinoma, bronchial adenoma, chondromatous hamartoma (non-cancerous) and sarcoma (cancerous ); cardiac cancer such as myxoma, fibroids and rhabdomyomas; bone cancers such as osteochondromas, chondromas, chondroblastomas, chondromyxoid fibromas, osteoid osteomas, giant cell tumors, chondrosarcoma, multiple myeloma, osteosarcoma, fibrosarcomas, malignant fibrous histiocytomas, Ewing's tumor (Ewing's sarcoma) and reticular cells; brain cancer such as gliomas (eg, glioblastoma multiforme), anaplastic astrocytomas, astrocytomas, oligodendrogliomas, medulloblastomas, chordoma, Schwannomas, ependymomas, meningiomas, pituitary adenoma, pinealoma, osteomas, hemangioblastomas, craniop-pharyngiomas, cranioppharymomas, chorgioblastomas, chordioppharymomas, angio-pharyngiomas ; digestive system cancers such as leiomyomaepidermoid epidermoid carcinoma, adenocarcinoma, leiomyosarcoma, stomach adenocarcinoma, intestinal lipomas, intestinal neurofibromas, intestinal fibromas, large intestine polyps, and colorectal cancers; liver cancers such as hepatocellular adenomas, hemangioma, hepatocellular carcinoma, fibrolamellar carcinoma, cholangiocarcinoma, hepatoblastoma and angiosarcoma; renal cancers such as renal adenocarcinoma, renal cell carcinoma, hypernephroma and transitional cell carcinoma of the renal pelvis transitional cell; bladder cancers; hematologic cancers such as acute lymphocytic (lymphoblastic) leukemia, acute myeloid leukemia (myelocytic, myelogenous, myeloblastic, myelomonocytic), chronic lymphocytic leukemia (eg, Sezary's syndrome and hairy cell leukemia), chronic myelocytic leukemia (myeloid, myelogenous, granulocytic) , Hodgkin's lymphoma, non-Hodgkin's lymphoma, B-cell lymphoma, mycosis fungoid, and myeloproliferative disorders (including myeloproliferative disorders such as polycythemia vera, myelofibrosis, thrombocythemia, and chronic myelocytic leukemia); skin cancers such as basal cell carcinoma, squamous cell carcinoma, melanoma, Kaposi's sarcoma, and Paget's disease; head and neck cancers; eye-related cancers such as retinoblastoma and intraocular melanocarcinoma; male reproductive system cancers such as benign prostatic hyperplasia, prostate cancer, and testicular cancers (eg, seminoma, teratoma, embryonic carcinoma, and choriocarcinoma); breast cancer; cancers of the female reproductive system such as cancer of the uterus (endometrial carcinoma), cervical cancer (cervical carcinoma), ovarian cancer (ovarian carcinoma), vulvar carcinoma, vaginal carcinoma, fallopian tube cancer and hydatidiform mole; thyroid cancer (including papillary, follicular, anaplastic, or medullary cancer); pheochromocytomas (adrenal gland); non-cancerous growths of the parathyroid glands; pancreatic cancers; and hematologic cancers such as leukemias, myeloma, non-Hodgkin's lymphomas, and Hodgkin's lymphomas.
[00161] In some other modalities, the disorder is an autoimmune disease. Examples of autoimmune diseases that can be treated with the binding molecules include autoimmune encephalomyelitis, lupus erythematosus and rheumatoid arthritis. The binding molecule can also be used to treat inflammation (such as allergic asthma) and graft-versus-host disease.
In another aspect, the present invention provides a method of enhancing an immune response in a mammal, which comprises administering to the mammal a therapeutically effective amount of a binding molecule provided by the invention. In some embodiments, the binding molecule is a 4-1BB antibody, or antigen-binding fragment thereof, and the mammal is a human. In yet another embodiment, the binding molecule is a 4-1BB agonistic antibody or antigen-binding fragment thereof. The expression "enhancement of the immune response" or its grammatical variations, means to stimulate, elicit, elevate, enhance or enhance any response of the immune system of a mammal. The immune response can be cellular response (ie, cell-mediated, such as mediated by cytotoxic T lymphocytes) or humoral response (ie, antibody-mediated response) and can be primary or secondary immune response. Examples of enhanced immune response include increased CD4+ helper T cell activity and cytolytic T cell generation. The enhancement of the immune response can be assessed using a range of in vitro or in vivo measurements known to those skilled in the art, including, but not limited to, cytotoxic T lymphocyte assays, cytokine release (eg, IL-2 production), regression tumors, survival of tumor-bearing animals, antibody production, immune cell proliferation, expression of cell surface markers and cytotoxicity. Typically, the methods of the invention enhance the immune response by a mammal as compared to the immune response by an untreated mammal or an untreated mammal using the claimed methods. In one embodiment, the binding molecule is used to enhance a human's immune response to a microbial pathogen (such as a virus). In another embodiment, the binding molecule is used to enhance a human's immune response to a vaccine. The binding molecule can be a 4-1BB agonist or antagonist. In some embodiments, the binding molecule is a 4-1BB agonist. In one embodiment, the method enhances a cellular immune response, especially cytotoxic T cell response. In another embodiment, the cellular immune response is a helper T cell response. In yet another modality, the immune response is cytokine production, especially IL-2 production. The binding molecule can be used to enhance a human's immune response to a microbial pathogen (such as a virus) or to a vaccine. The binding molecule can be a 4-1BB agonist or antagonist. In some embodiments, the binding molecule is a 4-1BB agonist.
In the practice of therapeutic methods, the binding molecules can be administered alone as monotherapy or administered in combination with one or more additional therapeutic agents or therapies. Therefore, in another aspect, the present invention provides a combined therapy which comprises a binding molecule combined with one or more additional therapeutics or agents for separate, sequential or simultaneous administration. The term "additional therapy" refers to a therapy that does not employ a binding molecule provided by the invention as a therapeutic agent. The term "additional therapeutic agent" refers to any therapeutic agent other than a binding molecule provided by the invention. In a specific aspect, the present invention provides a combination therapy for the treatment of cancer in a mammal, which comprises administering to the mammal a therapeutically effective amount of a binding molecule provided by the invention in combination with one or more additional therapeutic agents. In another embodiment, the mammal is a human being.
[00164] A wide variety of cancer therapeutic agents can be used in combination with a binding molecule provided by the present invention. Any person skilled in the art will recognize the presence and development of other cancer therapies that can be used in combination with the methods and binding molecules of the present invention and will not be restricted to the forms of therapy presented in this specification. Examples of categories of additional therapeutic agents that can be used in combination therapy to treat cancer include (1) chemotherapeutic agents, (2) immunotherapeutic agents, and (3) hormonal therapeutic agents.
The term "chemotherapeutic agent" refers to a chemical or biological substance that can be used to cause the death of cancer cells or to interfere with the growth, division, repair and/or function of cancer cells. Examples of chemotherapeutic agents include those described in WO 2006/088639, WO 2006/129163 and US 20060153808, the contents of which are incorporated herein by reference in this patent application. Examples of specific chemotherapeutic agents include: (1) alkylating agents such as chlorambucil (LEUKERAN), mcyclophosphamide (CYTOXAN), ifosfamide (IFEX), mechlorethamine hydrochloride (MUSTARGEN), thiotepa (THIOPLEX), streptozotocin (ZANOSAR), carmustine (BICNU, GLIADEL WAFER), lomustine (CEENU) and dacarbazine (DTIC-DOME); (2) alkaloids or alkaloids from the vinca plant, including cytotoxic antibiotics such as doxorubicin (ADRIAMYCIN), epirubicin (ELLENCE, PHARMORUBICIN), daunorubicin (CERUBIDINE, DAUNOXOME), nemorubicin, idarubicin (IDAMYCONED) . dactinomycin (actinomycin D, COSMEGEN), plicamycin (MITHRACIN), mitomycin (MUTAMYCIN) and bleomycin (BLENOXANE), vinorelbine tartrate (NAVELBINE), vinblastine (VELBAN), vincristine (ONCOVIN) and vindesine (ELDISINE); (3) antimetabolite such as capecitabine (XELODA), cytarabine (CYTOSAR-U), fludarabine (FLUDARA), gemcitabine (GEMZAR), hydroxyurea (HYDRA), methotrexate (FOLEX, MEXATE, TREXALL), Nelarabine (ARRANON), trimetrexate (NEUTREXIN ) and pemetrexed (ALIMTA); (4) pyrimidine antagonists such as 5-fluorouracil (5-FU); capecitabine (XELODA), raltitrexede (TOMUDEX), tegafur-uracil (UFTORAL) and gemcitabine (GEMZAR); (5) taxanes such as docetaxel (TAXOTERE), paclitaxel (TAXOL); (6) platinum drugs such as cisplatin (PLATINOL), carboplatin (PARAPLATIN) and oxaliplatin (ELOXATIN); (7) topoisomerase inhibitors such as irinotecan (CAMPTOSAR), topotecan (HYCAMTIN), etoposide (ETOPOPHOS, VEPESSID, TOPOSAR) and teniposide (VUMON); (8) epipodophyllotoxins (podophyllotoxin derivatives), such as etoposide (ETOPOPHOS, VEPESSID, TOPOSAR); (9) folic acid derivatives such as leucovorin (WELLCOVORIN); (10) nitrosoureas such as carmustine (BiCNU), lomustine (CeeNU); (11) receptor tyrosine kinase inhibitors, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGF), insulin receptor, insulin-like growth factor receptor (IGFR), factor receptor hepatocyte growth factor (HGFR) and platelet-derived growth factor receptor (PDGFR) such as gefitinib (IRESSA), erlotinib (TARCEVA), bortezomib (VELCADE), imatinib mesylate (GLEEVEC), genefitinib, lapatinib, sorafenib, thalidomide , sunitinib (SUTENT), axitinib, rituximab (RITUXAN, MABTHERA), trastuzumab (HERCEPTIN), cetuximab (ERBITUX), bevacizumab (AVASTIN) and ranibizumab (LUCENTIS), lym-1 (ONCOLYM), antibodies against the factor 1 receptor insulin-like growth (IGF-1R) which are described in WO2002/053596); (12) angiogenesis inhibitors such as bevacizumab (AVASTIN), suramin (GERMANIN), angiostatin, SU5416, thalidomide and matrix metalloproteinase inhibitors (such as batimastat and marimastat) and those described in WO2002055106; and (13) proteasome inhibitors such as bortezomib (VELCADE).
[00166] The term "immunotherapeutic agent" refers to a chemical or biological substance capable of enhancing a mammalian immune response. Examples of immunotherapeutic agents include: Bacillus Calmette-Guerin (BCG); cytokines such as interferons; vaccines such as personalized immunotherapy MyVax, Onyvax-P, Oncophage, GRNVAC1, FavId, Provenge, GVAX, Lovaxin C, BiovaxID, GMXX and NeuVax; and antibodies such as alentuzumab (CAMPATH), bevacizumab (AVASTIN), cetuximab (ERBITUX), gentuzunab ozogamycin (MYLOTARG), ibritumomab tiuxetan (ZEVALIN), panitumumab (VECTIBIX), rituximab (RITUXAN, MABTHERA), trastuzumab (MYLOTARG) ), ipilimumab (YERVOY) tremelimumab, CAT-3888, OX40 receptor agonist antibodies (as described in WO2009/079335), CD40 receptor agonist antibodies (as described in WO2003/040170 and TLR-9 agonists (as those described in WO2003/015711, WO2004/016805 and WO2009/022215).
The term "hormonal therapeutic agent" refers to a chemical or biological substance that inhibits or eliminates the production of a hormone or that inhibits or neutralizes the effect of a hormone on the growth and/or survival of cancer cells. Examples of such agents suitable for the methods of this invention include those described in US20070117809. Examples of specific hormonal therapeutic agents include tamoxifen (NOLVADEX), toremifene (Fareston), fulvestrant (FASLODEX), anastrozole (ARIMIDEX), exemestane (AROMASIN), letrozole (FEMARA), megestrol acetate (MEGACE), goserelin (ZOLADEX) and leuprolide (LUPRON). The binding molecules of this invention can also be used in combination with non-drug hormonal therapies such as (1) surgical methods that remove all or part of the organs or glands that participate in hormone production, such as the ovaries, the testes, the adrenal gland and pituitary gland (2) radiation treatment, in which the patient's organs or glands are subjected to radiation in sufficient quantity to inhibit or eliminate the production of the targeted hormone.
[00168] Combination therapy to treat cancer also encompasses a binding molecule combined with surgery to remove a tumor. The binding molecule can be administered to the mammal before, during or after surgery.
[00169] Combination therapy to treat cancer also encompasses a binding molecule combined with radiotherapy, such as ionizing (electromagnetic) radiation therapy (eg X-rays or gamma rays) and particle beam radiation therapy (eg , linear high energy radiation). The radiation source can be internal or external to the mammal. The binding molecule can be administered before, during or after radiotherapy.
The binding molecules and compositions provided by the present invention may be administered by any suitable enteral or parenteral route of administration. The term "enteral route" of administration refers to administration via any part of the gastrointestinal tract. Examples of enteral routes include the oral, mucosal, buccal and rectal or intragastric routes. "Parental route" of administration refers to a route of administration other than the enteral route. Examples of parenteral routes of administration include intravenous, intramuscular, intradermal, intraperitoneal, intratumoral, intravesical, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, transtracheal, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal, subcutaneous, administration, or topical administration. Antibodies and compositions of the invention can be administered using any suitable method, such as by oral ingestion, nasogastric tube, gastrostomy tube, injection, infusion, implantable infusion pump and osmotic pump. The proper route and method of administration may vary depending on such factors as the specific antibody in use, the desired rate of absorption, the formulation or dosage form used, the type or severity of the disorder being treated, the specific site of action. and patient conditions, and can be quickly selected by the technician in the field.
The term "therapeutically effective amount" of a binding molecule refers to an amount that is effective for the intended therapeutic purpose. For example, in the context of enhancing an immune response, a "therapeutically effective amount" is any amount that is effective in stimulating, eliciting, elevating, ameliorating or enhancing any response of a mammal's immune system. In the context of treating a disease, a "therapeutically effective amount" is any amount that is sufficient to elicit any desirable or beneficial effect on the mammal being treated. Specifically, in the treatment of cancer, examples of desirable or beneficial effects include inhibition of further growth or spread of cancer cells, death of cancer cells, inhibition of cancer relapse, reduction of pain associated with cancer, or improved survival of the mammal. The therapeutically effective amount of an antibody against 4-1BB generally ranges from approximately 0.001 to approximately 500 mg/kg and more generally from approximately 0.01 to approximately 100 mg/kg of mammalian body weight. For example, the amount may be approximately 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 5 mg/kg, 10 mg/kg, 50 mg/kg or 100 mg/kg of mammal body weight . In some embodiments, the therapeutically effective amount of an antibody against 4-1BB is in the range of approximately 0.01 - 30 mg/kg of mammal body weight. In some other embodiments, the therapeutically effective amount of an antibody against 4-1BB is in the range of approximately 0.05 - 15 mg/kg of mammal body weight. The precise level of dose to be administered can be quickly determined by the person skilled in the art and will depend on certain factors, such as the type and severity of the disorder being treated, the specific binding molecule employed, the route of administration, the time of administration, the duration of treatment, the specific additional therapy employed, the age, sex, weight, condition, general health, and previous medical history of the patient being treated, and similar factors well known in the medical arts.
[00172] A binding molecule or composition is usually administered on multiple occasions. Intervals between single doses can be, for example, weekly, monthly, every three months or annually. An exemplary treatment regimen requires administration once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every three months or once every three to six months. Typical dose schedules for a 4-1BB antibody include 1 mg/kg body weight or 3 mg/kg body weight via intravenous administration, using one of the following administration schedules: (i) every four weeks for six doses, then every three months; (ii) every three weeks; (iii) 3 mg/kg body weight once followed by 1 mg/kg body weight every three weeks.
[00173] The present invention is illustrated in more detail by the following examples, which are not to be construed as further limitation. The contents of all figures and all references, patents, patent application publications cited throughout this specification are hereby expressly incorporated in their entirety by reference in this patent application. EXAMPLES EXAMPLE 1: Generation of Fab Fragments That Bind 4-1BB
Certain antibodies provided by the present invention were originally generated from Fabs that bind to human 4-1BB. Fabs were selected from a phage display library, the MorphoSys HuCAL GOLD® phagemid library, followed by affinity selections (panning) alternating 4-1BB FC and cells expressing human 4-1BB. These Fabs include those designated as "Fab-6032", "Fab-7361", "Fab-7480" and "Fab-7483". Antibodies against 4-1BB, MOR-6032, MOR-7361, MOR-7480 and MOR-7483 described in this patent application were generated from "Fab-6032", "Fab-7361", "Fab-7480" and "Fab-7483", respectively. The amino acid sequence of the light chain variable region and heavy chain variable region of a given Fab are identical to the amino acid sequence of the light chain variable region and heavy chain variable region, respectively, of an illustrative antibody, whose designation share the same numerical representation with the Fab designation. For example, the Fab-7480 and the MOR-7480 antibody have identical amino acid sequences for their light chain variable region and their heavy chain variable region, respectively.
[00175] The phagemid library is based on the HuCAL® concept (Knappik et al., 2000, J. Mol. Biol. 296(1):57-86) and employs CysDisplayTM technology for displaying the Fab on the surface of the phage (Lohning, WO 01/05950). HuCAL GOLD® offers the option of selections performed with six isolated sub-libraries, each comprising a VH master gene (VH1, VH2, VH3, VH4, VH5, VH6) combined with all seven VL master genes or of performing selections using combined phage clusters. Phages for the first round of affinity selections were prepared by Hyperphage (M13KO7ΔpIII, obtained from Progen, Heidelberg, Germany). HuCAL GOLD® is described in detail in Christine Rothe, et. al, J. Mol. Biol. (2008) 376, 1182-1200.
Solid phase affinity selection was performed using human 4-1BB-recombinant Fc (R&D Systems, Cat. No. 8384B; Minneapolis, MN). EXAMPLE 2: Characterizations of Fabs
The characterizations of the four Fabs described in Example 1 were determined in the assays described below, using the monovalent Fab format comprising a Fab with a Flag/His tag. 2A. Affinity determined with the equilibrium solution titration (SET) method
[00178] The affinity (expressed in KD) of the four Fabs was determined by the SET method, using Meso Scale Discovery ("MSD") instrumentation. Antibody protein monomer fractions were used (at least 90% monomer content, analyzed by SEC analytical; Superdex75 (Amersham Pharmacia) for Fab or Tosoh G3000SWXL (Tosoh Bioscience) for IgG, respectively).
[00179] The determination of affinity in solution was performed basically as described in the literature (Friguet et al. 1985). In order to improve the sensitivity and accuracy of the SET method, it was transferred from classic ELISA to ECL-based technology (Haenel et al. 2005).
[00180] Goat anti-human specific fragments (Fab)2 antibodies 1 mg/ml (Dianova) were labeled with Sulfo-TAGTM NHS-Ester MSD (Meso Scale Discovery, Gaithersburg, MD, USA) according to the manufacturer's instructions .
[00181] The experiments were performed in polypropylene and PBS microtiter plates, pH 7.4, with 0.5% BSA and 0.02% Tween 20 as assay buffer. Unlabeled human 4-1BB was diluted in a 2nd series, starting with a concentration at least 10 times higher than the expected KD. Antigen-free wells were used to determine Bmax values; wells with assay buffer were used to determine background. After the addition of, for example, 30 pM Fab (final concentration in final volume of 60 µL), the mixture was incubated overnight at room temperature. The applied concentration of Fab was similar to or below the expected KD.
Standard MSD plates were coated with 0.05 µg/ml human 4-1BB in PBS (30 µl/well), incubated overnight and blocked with 3% BSA in PBS for 1 hour. After washing the plate with assay buffer, the balanced samples were transferred to those plates (30 µL per well) and incubated for 20 minutes. After washing, 30 μL/well of the Sulfo-tag MSD-labelled detection antibody (goat anti-(Human)2) in a final dilution of 1:1500 was added to the MSD plate and incubated for 30 minutes in an Eppendorf shaker (700 rpm).
After washing the plate and adding 30 μL/well MSD Reading T Buffer with surfactant, electrochemiluminescence signals were detected with a Sector Imager 6000 (Meso Scale Discovery, Gaithersburg, MD, USA).
[00184] Data were evaluated with XLfit software (IDBS), applying custom fit fit templates. For the determination of KD of Fab molecules, the fit model below was used (Haenel et al., 2005) and modified according to Abraham et al. (1996, J. Molec. Recog. 9(5-6):456-461):

[00185] [Fab]t: Total applied concentration of Fab
[00186] x: Total applied concentration of soluble antigen (binding sites)
[00187] Bmax: Maximum Fab signal without antigen
[00188] KD: Affinity
[00189] The results are shown in Table 3. 2B. Biacore KD determination in directly coated antigen
[00190] For the determination of KD, Fab monomeric fractions (at least 90% monomer content, analyzed by analytical SEC; Superdex75, Amersham Pharmacia) were used as analyte. Binding to immobilized antigen was analyzed using a BIAcore3000 instrument (Biacore, Sweden).
The kinetic constants for the kon and koff rates were determined with serial dilutions of the respective Fab covalently linked to the immobilized antigen CD137/4-1BB HUMAN using the Biacore 3000 instrument (Biacore, Uppsala, Sweden). For the covalent immobilization of the antigen, standard EDC-NHS amine coupling chemistry was used. Kinetic measurements were performed in HBS-EP (10 mM HEPES; pH 7.4; 150 mM NaCl; 3 mM EDTA; 0.005% Tween 20) at a flow rate of 20 μl/minute, using Fab concentrations ranging from approximately 16 at 500 nM. The injection time for each concentration was 1 minute, followed by a dissociation phase for at least 3 minutes. For regeneration, one or more injections of 5 μL of Glycine/HCl, pH 2, were used.
[00192] For KD estimation of whole IgG molecules, IgGs were injected into an F1 sensor chip with a low density of covalently immobilized human 4-1BB (approx. 130 RU), using a 2nd serial dilution with concentrations ranging from 16 to 500 nM. The sensorgrams were evaluated using a qualitative comparison bivalent fit model to rank the corresponding KD values.
[00193] All sensorgrams were fitted using the BIA evaluation software 3.1 (Biacore). The results are shown in Table 3. 2C. Binding of Fabs in ELISA Assay
Binding of the four Fabs was determined using standard ELISA techniques on human 4-1BB/Fc. Directly coated. The results are shown in Table 3. 2D. Binding of Fabs in FACS Assay
Binding of the four Fabs was determined using standard FACS techniques in stably transfected HEK293 cells expressing human 4-1BB, as well as in negative control 300.19 cells (murine B cell lineage). The results are shown in Table 3. Table 3. Binding properties of Fabs
EXAMPLE 3: Characterization of IgGs
Several Fabs obtained from affinity selection as described herein, including Fab-6032, Fab-7361, Fab-7480 and Fab-7483, were selected for conversion to full length antibodies in IgG1 and IgG4 formats for more detailed characterizations as described in this example. The four illustrative antibodies identified in this example, i.e., MOR-6032, MOR-7361, MOR-7480 and MOR-7483, were converted from Fab-6032, Fab-7361, Fab-7480 and Fab-7483, respectively. Antibodies in IgG format were expressed and purified and then characterized in ELISA, FACS and luciferase reporter gene assays. 3A. Conversion to IgG
In order to express complete IgG, heavy (VH) and light (VL) chain variable domain fragments were subcloned from Fab expression vectors into pMorph®_hIgG vectors appropriate for human IgG1 and human IgG4. 3B. Transient expression and purification of human IgG
Transient expression of complete human IgG was performed in HKB11 cells, which were transfected with IgG heavy and light chain expression vectors in a 1:1 ratio. Cell culture supernatant was harvested after transfection and its volume increased to 3 times that of transfection, respectively. The supernatant was released by centrifugation and filtration and then subjected to standard protein A affinity chromatography (MabSelect SURE, GE Healthcare). Proteins were eluted and neutralized. Further further processing involved buffer exchange and sterile filtration. Protein concentrations were determined by UV spectrophotometry. IgG purity was analyzed under denaturing, reducing and denaturing, non-reducing conditions on SDS-PAGE or using Agilent's BioAnalyzer. HP-SEC was performed to analyze native-state IgG preparations. 3C. Characterization of IgGs in an ELISA assay
[00199] IgGs were used for characterization of binding by ELISA in human 4-1BB/Fc and mouse 4-1BB/Fc in direct coat configuration. Table 4 presents ELISA binding results for MOR-6032, MOR-7361, MOR-7480 and MOR-7483 antibodies, all in IgG1 format. Table 4. IgG1 binding in ELISA assay
3D. Antibody Binding Selectivity (FACS Assay)
The selectivity of antibodies by 4-1BB was evaluated against the protein of the extracellular domain of 4-1BB and by other members of the TNFR superfamily. These receptors included CD40 (TNFRSF5) and OX-40 (CD134, TNFRSF4). IgGs were used for characterization of FACS binding in HEK293 cells as a negative control, as well as in HEK293T-h4-1BB cells, stably transfected and expressing human 4-1BB, in 300.19 cells, stably transfected and expressing OX-40, and in cells 300.19 stably transfected and expressing CD40. FACS binding results for MOR-6032, MOR-7361, MOR-7480 and MOR-7483 antibodies, all in IgG1 format, are shown in Table 5. No significant binding was observed to OX-40 or CD40 on concentrations up to 1000 nM, demonstrating that antibodies are at least 100 times more selective for 4-1BB compared to other tested family members. Table 5. Antibody binding selectivity (IgG1) in FACS assay
3E. Characterization of IgGs in a luciferase reporter gene assay
IgGs were also characterized for binding in a luciferase reporter gene assay using HEK293T-h4-1BB cells in a plate-bound assay and a cross-linking assay. Table 6 shows the results of the luciferase reporter gene assay for MOR-6032, MOR-7361, MOR-7480 and MOR-7483 antibodies, all in IgG1 format. Table 6. Characterization of IgG1 in luciferase reporter gene assay

EXAMPLE 4: Structural characterization of MOR-6032, MOR-7361, MOR-7480 and MOR-7483 antibodies
The procedures described above in Examples 1 - 3 were used to produce several complete IgG2 anti-human-4-1BB antibodies, including the antibodies designated "MOR-6032", "MOR-7361", "MOR-7480" and " MOR-7483." The cDNA sequences encoding the heavy and light chain variable regions of the monoclonal antibodies MOR-6032, MOR-7361, MOR-7480 and MOR-7483 were obtained using standard PCR techniques and sequenced using standard techniques of DNA sequencing.
[00203] The nucleotide and amino acid sequences of the heavy chain variable region, the complete heavy chain of the IgG2 subclass, the light chain variable region, and the complete light chain of the antibodies MOR-6032, MOR-7361, MOR-7480, MOR-7480.1, MOR-7480.2, MOR-7483, MOR-7483.1 and MOR-7483.2 are provided in the present invention; an index of the SEQ ID NOs for these sequences is shown in Table 1.
Comparison of the immunoglobulin heavy chain sequence of MOR-6032 to known germline immunoglobulin heavy chain sequences demonstrated that the heavy chain of MOR-6032 utilizes a VH segment of VH 1-69 from the human germline , a D segment from 4-23 of the human germline and a JH segment from JH 4a of the human germline.
Further analysis of the VH sequence of MOR-6032, using the Kabat system for determining CDR regions, led to the delineation of the heavy chain H-CDR1, H-CDR2 and H-CDR3 regions as shown in the SEQ ID NOs: 1, 2 and 3 respectively.
Comparison of the immunoglobulin heavy chain sequence of MOR-7361 to known germline immunoglobulin heavy chain sequences demonstrated that the 7361 heavy chain utilizes a VH segment from germline VH 3-23, a segment D from 2-8 of the human germline and a JH segment from JH 4a of the human germline.
Further analysis of the VH sequence of MOR-7361, using the Kabat system for determining CDR regions, led to the delineation of the heavy chain H-CDR1, H-CDR2 and H-CDR3 regions as shown in the SEQ ID NOs: 15, 16 and 17, respectively.
Comparison of the immunoglobulin heavy chain sequences of MOR-7480 and MOR-7483 to known germline immunoglobulin heavy chain sequences demonstrated that the heavy chain of 7480 and 7483 utilize a VH segment from VH 5 from the human germline, a D segment from 5-18 of the human germline and a JH segment from the JH 4a of the human germline.
Further analysis of the 7480 and 7483 VH sequences, using the Kabat system for determining CDR regions, led to the delineation of the H-CDR1, H-CDR2 and H-CDR3 regions as shown in SEQ ID NOs: 29 , 30 and 31, respectively.
Comparison of the immunoglobulin light chain sequences of MOR-6032, MOR-7361, MOR-7480 and MOR-7483 to known germline immunoglobulin light chain sequences demonstrated that the light chains of 6032, 7361, 7480 and 7483, all use a VL segment from germline À3-r and a JL segment from germline JL 3b.
Further analysis of the VL sequence of MOR-6032, using the Kabat system for determining CDR regions, led to the delineation of the CDR1, CDR2 and CDR3 regions of the light chain, as shown in SEQ ID NOs: 6, 7 and 8, respectively.
[00212] Further analysis of the VL sequence of MOR-7361, using the Kabat system for determining CDR regions, led to the delineation of the L-CDR1, L-CDR2 and L-CDR3 regions, as shown in SEQ ID NOs: 20, 21 and 22, respectively.
[00213] Further analysis of the VL sequence of MOR-7480,L using the Kabat system for determining CDR regions, led to the delineation of the L-CDR1, L-CDR2 and L-CDR3 regions, as shown in SEQ ID NOs : 34, 35 and 36, respectively.
Further analysis of the VL sequence of MOR-7483, using the Kabat system for determining CDR regions, led to the delineation of the L-CDR1, L-CDR2 and L-CDR3 regions, as shown in SEQ ID NOs: 34, 35 and 55, respectively. EXAMPLE 5: Germline-aligned versions of the MOR-7480 AND MOR-7483 antibodies
[00215] In order to minimize the immunogenicity of the MOR-7480 and MOR-7483 antibodies, several amino acid residues were reverse mutated to the germline sequence in the following manner. A germline aligned version of MOR-7480, designated MOR-7480.1, was prepared by returning two amino acids in the FR1 region of the variable heavy chain to the germline sequence. More specifically, Q at amino acid residue number 1 was returned to E of the germline and K at amino acid residue number 19 was returned to R. The two amino acid residues that were swapped in the heavy chain variable region can be seen by comparing the sequence of amino acids of MOR-7480 (SEQ ID NO: 32) with that of MOR-7480.1 (SEQ ID NO: 43). In the light chain variable region of MOR-7480, five amino acids in the FR1 region (D1S, I2Y, A13S, R19S, S21T), two amino acids in the FR2 region (A42S, V45L), and one in the FR3 region (E80M) were reversed to the germline sequence. The eight amino acids that were exchanged in the light chain variable region can be seen by comparing the amino acid sequence of MOR-7480 (SEQ ID NO: 37) with that of MOR-7480.1 (SEQ ID NO: 45).
In addition, a third version of MOR-7480 was prepared, starting with the light chain variable region sequence of MOR-7480.1 (SEQ ID NO: 45) and reversing L45 back to V to produce MOR-7480.2 ( SEQ ID NO:51).
A "germline-aligned" version of MOR-7483, designated MOR-7483.1, was prepared by reverse mutating two amino acids in the FR1 region of the variable heavy chain to the germline sequence. Germline-aligned versions can be prepared by starting with the germline version of the antibody chain and then changing the desired amino acids in the CDRs or any combination of mutations initiated from any version. To produce MOR-7483.1, Q at amino acid residue number 1 was returned to germline E and K at amino acid residue number 19 was returned to R. The two amino acid residues that were swapped in the heavy chain variable region can be seen comparing the sequence of MOR-7483 (SEQ ID NO: 32) with that of MOR-7483.1 (SEQ ID NO: 43). In the light chain variable region of MOR-7483, five amino acids in the FR1 region (D1S, I2Y, A13S, R19S, S21T), two amino acids in the FR2 region (A42S, V45L) and one in the FR3 region (E80M) were reverted to germline sequence. The eight amino acids that were exchanged in the light chain variable region can be seen by comparing the amino acid sequence of MOR-7483 (SEQ ID NO: 56) with that of MOR-7483.1 (SEQ ID NO: 60).
[00218] In addition, a third version of MOR-7483 was prepared by reverse mutating at L45 the light chain variable region sequence from MOR-7483.1 (SEQ ID NO:60) to germline V45 to produce MOR-7483.2 ( SEQ ID NO:64). EXAMPLE 6: IN VITRO properties OF ANTIBODIES, including germline aligned versions Antibody Binding Affinities (BIAcore Assay)
[00219] The binding kinetics of certain antibodies that bind to human 4-1BB were measured by surface plasmon resonance (SPR) technology using a Biacore 3000 instrument (GE Healthcare). Recombinant Chimera protein human 4-1BB/Fc, comprising amino acids 24 - 186 of SEQ ID NO:68, was purchased from R&D Systems Inc. (#838-4B). The lyophilized protein was dissolved in buffer containing 150 mM NaCl, 25 mM HEPES, pH 8.0, 6 mM MgCl 2 , 0.005% polysorbate 20 and 0.5 mM sodium azide to a final concentration of 80 nM based on predicted molecular weight (44 .8 kDa) reported by R&D Systems. The Fc part of the molecule was cleaved by treatment with Bovine Factor Xa (Pierce, no. 32521) in 150 mM NaCl, 25 mM HEPES, pH 8.0, 6 MgCl2 6 mM, 0.005% polysorbate 20, 0.05 mM sodium azide, using incubation for 20 hours at 22 °C with % Factor Xa 3% (3 μg Factor Xa per 100 μg 4-1BB chimera). The 4-1BB part of the molecule comprises amino acid residues 24 to 186 of the human protein 4-1BB. Binding experiments were performed at 25°C in running buffer comprising 150 mM NaCl, 25 mM HEPES, pH 8.0, 6 mM MgCl 2 , 0.005% polysorbate 20 and 0.5 mM sodium azide. Antibodies were immobilized by standard amino coupling to a CM5 sensor chip (GE Healthcare) using a 0.1 mg/ml solution of the antibody in 10 mM sodium acetate and pH 5.0. The 4-1BB was injected at a concentration range of 80 nM to 0.16 nM, at a flow rate of 50 μL/minute, for 3.6 minutes followed by a 26-minute dissociation period, using the instrument's Kinject feature. Biacore 3000. The bound complex was regenerated by a 1 minute pulse of 10 mM phosphoric acid in water. Data analysis was performed with Scrubber2 software (BioLogic Software). The sensorgrams were fitted to a single Langmuir 1:1 binding model. The antibodies were shown to bind reversibly to recombinant human 4-1BB. The results (average values) are shown in Table 7. Binding to the 4-1BB extracellular domain (ELISA assay)
Human 4-1BB-IgG1Fc chimera (R&D Systems, Minneapolis, MN) was resuspended in Dulbecco's phosphate buffered saline (DPBS) containing 0.1% bovine serum albumin (BSA) to 0.2 mg /mL, and diluted with DPBS to a final concentration of 0.03 μg/mL. Nunc-Immuno Maxisorp 96-well plates were coated with the recombinant 4-1BB chimera at 0.1 ml per well, leaving empty wells for non-specific binding controls, and incubated at 4°C overnight. The 4-1BB solution was removed and the plates were washed three times with 0.2 ml wash buffer (0.05% Tween-20 in DPBS). 0.2 ml of blocking buffer (5% BSA, 0.05% Tween-20 in DPBS) was added to all wells, which were incubated at 4°C for 1 hour with mixing. Blocking buffer was removed and plates washed three times with 0.2 ml wash buffer. Serial dilutions of antibodies against 4-1BB under test were prepared in DPBS and 0.1 ml of diluted Ab was added per well. Plates were incubated for 1.5 hours at room temperature. The antibody solution was removed and the plates were washed three times with 0.2 ml wash buffer per well. Horseradish peroxidase labeled goat anti-human IgG F(ab')2 specific F(ab')2 antibody (Jackson Immunoresearch no. 109-036-097, West Grove, PA) was diluted 1:5000 with DPBS and 0. 1 ml added per well. Plates were incubated 1 hour at room temperature and washed with 0.2 ml per well of wash buffer. 0.1 mL of microwell SureBlue TMB peroxidase substrate (Kirkegaard & Perry Labs, Gaithersburg, MD) was added and incubated for 20 minutes at room temperature. The reaction was stopped by the addition of an equal volume of 2 M H2SO4, and the absorbance was read at 450 nm on a Molecular Devices Spectra Max 340 (Molecular Devices, Sunnyvale, CA). The results are shown in Table 8. Ligand binding competition (ELISA Assay)
Antibodies were tested for their ability to block the binding of the human 4-1BB chimera_IgG1Fc to the plate-bound recombinant 4-1BB (4-1BBL) ligand. Recombinant human 4-1BB ligand (Biosource/Invitrogen, Carlsbad, CA) was resuspended to 0.2 mg/ml in DPBS + 0.1% bovine serum albumin and then diluted to 1 µg/ml in DPBS. Nunc-Immuno MaxiSorp 96-well surface plates were coated with 0.1 ml/well of the 4-1BBL solution overnight at 4°C. The next day, the 4-1BBL solution was removed, and 0.2 ml of Blocking buffer (1% bovine serum albumin, 0.05% Tween-20 in DPBS) added and incubated at room temperature for 2 hours. During the blocking step, antibody stocks were diluted in a range of 8 ng/mL to 6 μg/mL in DPBS. Recombinant human 4-1BB_IgG1Fc (R&D Systems, Minneapolis, MN) was resuspended to 0.2 mg/ml in DPBS + 0.1% bovine serum albumin and then diluted to 0.02 µg/ml in DPBS. Blocked plates coated with 4-1BBL were washed three times with 0.2 ml wash buffer (0.05% Tween 20 in DPBS). 60 µL of antibody dilutions were added together with 60 µL of the 4-1BB_IgG1Fc chimera and incubated at room temperature for 1.5 hours. Plates were washed as described above. Horseradish peroxidase-labeled 6xHistidine anti-tag antibody (R&D Systems, Minneapolis MN on MAB050H) was diluted 1:1000 in DPBS, 50 µL of the resulting solution was added to the wells of the washed plates and incubated at room temperature for 1 hour. Plates were washed as previously described. 50 μL of TMB substrate solution was added to each well and incubated at room temperature for 20 minutes. The reaction was stopped with 50 μL of 0.2 N H2SO4, and the absorbance was read at 450 nm with a Molecular Devices plate reader. The results are shown in Table 8. Cross-reactivity of antibodies between species
The cross-species cross-reactivity of the exemplary antibodies was measured using primary peripheral blood mononuclear cells (PBMC) stimulated with phytohemagglutinin (PHA) from humans, cynomolgus monkey (cyno), dog and rat. Cells were isolated according to the procedure described below. Cells (~5.0 x 105 cells/tube) were washed once in ice-cold wash buffer (PBS, 2% FBS and 0.02% sodium azide) and 100 µL/tube conjugated to Alexa Fluor 647 or antibodies reactive against 4-1BB at 15.5 μg/ml (100 nM) were added to each sample, along with labeled antibodies against species-specific T cell marker. Antibodies used against T cell marker were as follows: FITC anti-human CD3e (BD Pharmingen, no 555332), FITC anti-rat CD3e (BD Pharmingen, no 559975), FITC anti-rabbit CD4 + FITC anti-CD8 rabbit (AbD Serotec no MCA799F and CA1576F), FITC anti-dog CD3e (AbD Serotec no MCA1774F) and anti-human CD3e/cyno PerCP (BD Pharmingen no 552851). Cells were incubated in the dark with the fluorochrome-labeled antibodies on ice for 30 minutes, washed three times and resuspended in 0.3 ml wash buffer for analysis. Antibody staining was measured and analyzed with Becton Dickinson FACS Calibur and FlowJo 8.8.2 software.
[00223] Isolation of human T lymphocytes. Human whole blood was collected in syringes containing 1.0 mL of 0.5 M EDTA and then transferred to Sigma Accuspin tubes (Sigma, St. Louis, MO) for isolation of peripheral blood mononuclear cells (PBMC) as described by the manufacturer . PBMCs were washed twice with DPBS containing 5 mM EDTA, and T lymphocytes were isolated via a T cell purification column as described by the manufacturer (R&D Systems, Minneapolis, MN). Briefly, PBMCs were resuspended in 2 ml of column buffer and loaded onto a previously washed glue for T cell isolation. PBMCs were incubated for 10 minutes at room temperature and T cells were eluted with column buffer, washed one. again and resuspended in TCM at 2 x 106 cells/ml, consisting of RPMI 1640 (Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (Sigma, St. Louis, MO) and L-glutamine (2 mM) , Hepes (10 mM), penicillin (100 U/ml), streptomycin (50 µg/ml) (Gibco, Grand Island, NY.).
[00224] Isolation of PBMCs from Cynomolgus. Cynomolgus whole blood (Bioreclamation; Hicksville, NY) was collected into CPT vacutainer tubes containing sodium citrate (BD; Franklin Lakes, NJ) which were then spun at 1500 x g for 20 minutes at room temperature. Tubes were shipped overnight at 4oC. The PBMC fraction was collected from the CPT tubes and washed 2x with PBS containing 5 mM EDTA. After the washing step, the PBMCs were counted and readjusted to 2 x 106 cells/ml in tissue culture medium (TCM). TCM medium consisted of RPMI 1640 (Sigma, St Louis, MO) supplemented with 10% fetal bovine serum (Sigma, St Louis, MO) and L-glutamine (2 mM), HEPES (10 mM), penicillin (100 U/ mL), streptomycin (50 µg/mL) purchased from Gibco (Grand Island, NY). Cells were stimulated with PHA 10 μg/ml PHA for 2-3 days to induce 4-1BB expression.
[00225] Isolation of canine PBMCs. Canine whole blood was collected in heparinized vacutainer tubes (BD; Franklin Lakes, NJ) and diluted 1:2 with PBS containing 5mM EDTA. After mixing, 4 mL of the diluted blood was carefully layered over 3 mL of Lympholyte-Mammal (Cedarlane Laboratories, Westbury, NY) and centrifuged at 800 x g for 20 minutes at 25 °C. The PBMC interface was collected, washed twice with PBS and resuspended to 2 x 106 cells/ml in TCM containing 10 μg/ml PHA (Remel, Lenexa, KS). Cells were cultured for 48-72 hours before being tested for antibody binding by flow cytometry.
[00226] Isolation of rat PBMCs. Rat whole blood was collected in heparinized vacutainer tubes (BD; Franklin Lakes, NJ) and diluted 1:3 with PBS containing 5 mM EDTA. After mixing, 6 mL of the diluted blood was carefully layered over 4.5 mL of Lympholyte-Mammal (Cedarlane Laboratories, Westbury, NY) and centrifuged at 800 x g for 20 minutes at 25 °C. The PBMC interface was collected, washed twice with PBS and resuspended to 2 x 106 cells/ml in TCM containing 10 μg/ml PHA (Remel, Lenexa, KS). Cells were cultured for 48-72 hours before being tested for antibody binding by flow cytometry.
The binding results are provided in Figure 1. Antibodies were found to bind to human and cyno 4-1BB with high affinity, whereas binding to dog and rat 4-1BB was not observed at concentrations of 100 nM, the highest concentration tested. Table 7: IgG antibody binding affinities (Biacore)
Table 8: Binding and competition values with ligand eg ELISA assay
epitope mapping
In order to determine the epitope binding region of agonist antibodies against 4-1BB, a series of mutations (Table 9) were made in the extracellular domain of human 4-1BB to the published sequence of canine 4-1BB (Seq of Ref. XM_845243). Table 9. Mutant extracellular domain of human 4-1BB

[00229] All human to canine mutations were prepared by Gene Dynamics LLC, (Portland or) in the retroviral expression vector pMSCVpuro (Clontech Laboratories Mountain View, CA). Additionally, the complete canine cDNA sequence was prepared by synthesizing the gene corresponding to Seq. of Ref. XM_845243.
[00230] Viral preparations were established by transient transfection of 293T cells at approximately 4050% confluence in T-75 flasks. After culture, the viral supernatant was then sterile filtered and subjected to concentration. Concentrated virus was collected and stored at -80 oC.
[00231] The genetic material of 300-19 cells in logarithmic growth was transferred with retroviruses, using the concentrated virus in 1:250 dilution plus 8 μg/ml polybrene in complete DMEM. After incubation for 24 hours, 2 μg/mL puromycin was added to the cultures and maintained for the duration of the study.
Positive expression of 4-1BB receptors by puromycin-selected clusters was confirmed by staining with polyclonal goat anti-human 4-1BB antibody 1 μg/ml (R&D Systems Inc.) plus (H+L) F(ab ')2 labeled with donkey anti-goat IgG (Jackson Immunoresearch Inc.) at 1:200 dilution. In order to determine the recognition of mutant 4-1BB receptors by the antibodies under test, the puromycin-selected pools were stained with a 100 nM dilution of the unlabeled primary antibody on ice for 30 minutes, followed by two washes with FACS buffer and (H +L) F(ab')2 labeled with species-specific donkey anti-IgG PE at 1:200 dilution. Cells were analyzed by FACS with BD FACS Calibur and FlowJo 8.8.6 software.
[00233] The relative coloration of each cell grouping is summarized in Table 10. Table 10. Relative coloration of each cell grouping


Differentiation of binding between antibodies with similar sequences (MOR-7480, MOR-7480.1, MOR-7480.2, MOR-7483 and MOR-7483.1) was discovered within the mutations of clone N&E.5, suggesting that the determinants for the antibody recognition reside within the mutant region.
In order to determine the relative affinity of these antibodies for the extracellular domain of human 4-1BB and for the mutant of the extracellular domain of 4-1BB, the N&E.5 mutant, a dose-response curve by FACS was determined for each antibody. MOR_7480, MOR_7480.1 and MOR_7480.2 labeled with Alexa Fluor 647 were diluted in FACS buffer starting at 1 µM in an 8-point 1:5 dilution series and used to stain 300-19, hu4-1BB precursor cell clusters , hu4-1BB N&E.5 and canine 4-1BB. Cells were analyzed by FACS with BD FACS Calibur and FlowJo 8.8.6 software. The geometric mean of fluorescence from each receptor expressing cluster was normalized to precursor cell staining and expressed in fold staining, and an EC50 dose-response determined. The EC50 summary is shown in Table 11. It was noted that the binding of MOR_7480.2 and MOR_7480 reduced more than 5-fold for the N&E.5 mutant of human 4-1BB. Table 11. EC50 (nM) of antibody binding

Antibody agonist activity (Luciferase activity assay)
293T cells expressing human 4-1BB together with a luciferase reporter stably integrated with NFkB were prepared. Cells were harvested, washed and resuspended in phenol red-free complete medium (DMEM containing 10% fetal bovine serum, HEPES buffer, non-essential amino acids and L-glutamine) at a density of 0.6 X 106 cells/ml. 50 µL of cells were seeded into each assay well of a 96-well white plate (PerkinElmer, Waltham, MA). Test antibodies were added to each well in the presence of a cross-linked goat anti-human IgG Fc antibody Fab' (Jackson ImmunoResearch, West Grove, PA) in a 2.5:1 ratio. The plate was incubated 5 hours at 37°C. 75 µL of Bright-Glo Luciferase reagent (Promega, Madison WI) was added, and the amount of luciferase activity was measured using a Packard TopCount NXT scintillation counter.
[00237] 293T cells expressing 4-1BB from cynomolgus monkeys were prepared by viral transduction and selection with 2 μg/mL puramicin from a stable pool. 293T cells expressing 4-1BB cyno were seeded in a T-75 flask until they reached approximately 60-70% confluence, then transfected with 10 μg pLuc_6xNFkB plus 0.1 μg pRL-CMV as a transfection control. Transfections were performed using Fugene 6 transfection reagent (Roche Indianapolis, IN) at a ratio of 6 µl Fugene to 1 µg plasmid DNA according to the manufacturer's instructions. The cells were harvested the following day, washed and resuspended in phenol red-free complete medium (DMEM containing 10% fetal bovine serum, non-essential amino acids and L-glutamine) at a density of 0.6 x 106 cells/ml. 50 µL of cells were seeded into each assay well of a 96-well white plate (PerkinElmer, Waltham, MA). Test antibodies were added to each well in the presence of a cross-linked goat anti-human IgG Fc antibody Fab' (Jackson ImmunoResearch, West Grove, PA) in a 2.5:1 ratio. The plate was incubated 5 hours at 37°C. 75 µL of luciferase assay reagent was added, and the amount of firefly luciferase activity was measured using a Packard TopCount NXT scintillation counter. Additionally, 75 µL of Stop & Glo reagent was added to assess Renilla luciferase activity was measured with Pakcard TopCount NXT scintillation counter. The results are shown in Figure 2. Antibody agonist activity (primary T cell IL-2 release assay)
Nunc Maxisorp 96-well plates were UV sterilized before being coated. Test antibodies were diluted in PBS to 60 μg/mL. 0.2 ml of the diluted Ab was divided into 2 wells of a 96-well polypropylene plate and serially diluted 1:3. 50 µl of the diluted Ab was added to the sterile 96-well Maxisorp assay plate and immediately 50 µl of the UCHT1 anti-human CD3ε clone (Biolegend San Diego, CA) 20 µg/ml was added. All plates were then incubated overnight at 4°C. The next day, Ab coated plates were washed 1x with PBS and 0.15 ml of RPMI complete medium was added to the wells of Nunc Maxisorp plates. Human T cells were isolated as described previously in this patent application, and 50 µl of purified T cells at 2 x 106 cells/ml (100,000 cells/well) were added to each well. Cells were incubated at 37°C, 5% CO 2 for 3 days. The supernatant from each well was collected and analyzed immediately or stored at -20oC prior to assay. Supernatants were diluted with complete media prior to IL-2 ELISA assay (R&D Systems, Minneapolis, MN). The results are shown in Figure 3. EXAMPLE 7: ANTIBODY-INDUCED EXPANSION OF HUMAN LEUKOCYTES AGAINST 4-1BB IN VIVO
[00239] The lack of detectable cross-reactivity of antibodies against 4-1BB with murine 4-1BB and the requirement for the presence of human immune cells made it necessary to develop models for functional evaluation in vivo of antibodies against 4-1BB. Mice with a NOD genetic background carrying severe combined immunodeficiency mutation (SCID) and a deficiency in the common gamma chain of the IL-2 receptor (commonly called NSG) are able to support the engraftment of large numbers of human peripheral blood leukocytes ( huPBL) and maintain the graft for at least 30 days (King, 2008, Clin. Immunol. 126:303314). This mouse model, also known as the huPBL-NSG model, was used to assess the functional effect of systemic in vivo administration of antibodies on human immune cells. Specifically, 6 million newly isolated human PBMCs were adoptively transferred via intravenous injection to NOD.Cg-Prkdcscid Il2rgtmlWjl/SzJ (NSG) host mice. Nine days after the PBMC injections, animals received a single 1 mg/kg dose of MOR7480, MOR7480.1 or IgG2 isotype control antibody by intraperitoneal injection. On Day 24 to 28 after PBMC engraftment, PBMC were stained with antibodies against human and murine CD45 as assessed by flow cytometry. Forward and side scatter profiles were used to determine a lymphocyte gate. According to Figure 4, MOR7480 and MOR7480.1 were able to enhance the expansion of human leukocytes, as evidenced by the increased proportion of human CD45+ cells in the peripheral blood of mice with grafts. For each group, n>6 mice.
In addition, MOR7480.1 treatment of cynomolgus monkeys increased proliferation among central memory cytotoxic T cells (CD8 TCM) in PBMC samples. Cynomolgus monkeys (2 animals per dose level) received a single intravenous injection of MOR7480.1 at the indicated dose. PBMCs were harvested 7 prior to antibody dose (pre-dose) and on the indicated study days in relation to MOR7480.1 administration (on Study Day 1). PBMCs were stained with antibodies to CD3, CD4, CD8, CD28, CD95 and Ki-67 and analyzed by flow cytometry. Data are collected in a Canto II (Beckton Dickinson) and analyzed with the DIVA software (Becton Dickinson). CD8 central memory cells were identified as CD3+, CD8+, CD28+ and CD95+. Data are shown for individual animals designated as (dose level-animal number) and are plotted as intra-animal change in Ki-67+ cell number from pre-study number {[(Ki-67 cell number) + cells on indicated day of study - number of Ki-67+ cells pre-dose)/no of Ki-67+ cells pre-dose]*100}. As shown in Figure 5, a 5-fold or greater increase in proliferating central memory T cells was observed during the first 7-13 days of the study in at least one animal from all groups treated with 0.3 mg/kg or dose bigger. EXAMPLE 8: Anti-Tumor Activity of Antibodies against 4-1BB (IN VIVO MODEL) PC3 human prostate cancer model
[00241] The lack of cross-reactivity in rodents of the antibodies against 4-1BB has prevented the use of standard models of syngeneic murine tumors or human graft for the evaluation of the human antitumor efficacy of the antibodies. Consequently, a new huPBL-SCID-Bg xenogenic tumor model in mice was generated using mouse SCID-Bg (CB.17/lcr.Cg PkrdcscidLystbg/Crl), which harbors functional murine T and B lymphocytes and NK cells without the mutation beige (Bg). The human antitumor efficacy of antibodies against 4-1BB was evaluated using this model as described below.
[00242] Human prostate cell line PC3 or human colon LOVO was obtained from the American Type Culture Collection and grown in RPMI-1640 (Invitrogen) enriched with the following Invitrogen supplements: L-glutamine, sodium pyruvate, non-amino acids essentials, penicillin/streptomycin, Hepes and 10% heat-inactivated fetal bovine serum (FBS; Cat. No. F2442, Sigma Aldrich). Cells were grown to confluence in T-225 Falcon flasks. Subsequently, cells were treated with trypsin (0.25% Trypsin-EDTA; Cat. No. 2500-056, Invitrogen) and growth was amplified in Hyperflasks (Cat. No.3319 Corning Life Sciences) for three days. Trypsin was used to harvest the cell line which was washed 3 times in ice-cold PRMI supplemented with 10% FBS. No more than 300 mL of peripheral blood was collected from healthy volunteers. Peripheral blood lymphocytes (PBMCs) were isolated from heparinized blood using Accuspin tubes according to the manufacturers protocol (Cat. No. A0561-100x 15 mL, Aldrich). Counted cell suspensions were combined in such a way that each mouse received an injection of 1.5 x 106 PBMCs and 3 x 106 tumor cells in a single 0.2 mL bolus injection in PBS. The combined cell suspension was washed twice with cold PBS, placed on ice and immediately injected into prepared mice.
[00243] For each mouse, a volume of 0.2 ml of the combined cell suspension was injected subcutaneously into the right flank of the animal and a single dose (0.2 ml) of antibody against 4-1BB or control antibody was applied by injection. subcutaneous on the left flank. Tumor was measured twice a week with a Pressier caliper for the duration of the experiments and body weights were recorded as well. Tumor volume was determined using the following calculation: length x width2 x 0.44= volume (mm3). The mice were removed if the tumor volume reached 2000 mm3 or if there was 20% weight loss by the animal before the end of the experiment. On Day 23, mice from all groups were sacrificed according to the procedure outlined by the IACUC (Figure 6). Percent inhibition of tumor growth was measured on the last day of the study and is calculated as 100-{1-(Treated end day/Control day end)}. Similar results were seen when tumors were measured on Day 6 after injection, and animals were randomized according to tumor volume and received a single dose of mAb against 4-1BB on Day 7 after implantation. For most studies, each group contained 8 mice. EXAMPLE 9: In vivo evaluation of antibody activity against 4-1BB in KNOCK IN mice to human 4-1BB Generation of knock in mice to human 4-1BB
[00244] In order to better address the immune modulating activities of human anti-4-1BB monoclonal antibodies that do not cross-react with murine H-1BB, a mouse model in which the mouse 4-1BB gene was replaced by the mouse 4-1BB gene. human 4-1BB gene was generated. Bacterial artificial chromosome (BAC) clones, carrying the human or murine 4-1BB genomic fragment, were ordered from Invitrogen (Carlsbad, CA.) and used to construct the 4-1BB targeting vector based on Red recombination technology /ET (Zhang, 1998, Nat Genet 20:123-128). First, a rescue vector was assembled into the pBR322 framework in such a way that, when opened by digestion with Xba1, the two murine/human chimeric homology arms (400 bps each) will retrieve from the human 4-1BB BAC clone the 19,994 bps from the genomic sequence of human 4-1BB, starting with the ATG translation start codon located in exon 2 and ending with the TGA stop codon in exon 8. Second, a neomycin expression cassette under the control of PGK promoters /EM7 was assembled and flanked by 100 base pairs (bps) of sequences homologous to intron 2 sequences of the human 4-1BB gene. This neomycin expression cassette was then targeted to the genomic fragment retrieved from human 4-1BB obtained in step 1. Finally, the genomic fragment retrieved from human 4-1BB, carrying the neomycin expression cassette, was targeted to a BAC clone to replace the murine 4-1BB gene with the modified human 4-1BB genomic fragment, from the start codon ATG to the stop codon TGA.
This BAC-targeted vector was electroporated into a mouse embryonic cell line with a C57BL/6NTAC background (PRX-BL6N #1, Primogenix, Laurie, MO.), following a standard protocol, and clones surviving selection with G418 (also known as geneticin) were screened by two Taqman assays against intron 2 and exon 8 of the murine 4-1BB gene to identify clones that had been modified at the murine 4-1BB locus by a homologous recombination mechanism. Of the 116 ES clones screened, 7 clones were shown to have lost an allele of the murine 4-1BB locus (targeting efficiency: 6%). Karyotype analysis and in situ hybridization (FISH) were performed by the Coriell Institute for Medical Research (Camden, N.J.). For clone LH15, 19 of 20 cells were 40XY and for LH80, 20 of 20 cells were 40XY. In both clones, FISH with a murine BAC clone carrying the 4-1BB gene as a probe showed a 4-1BB hybridization signal in each of the 4-chromosome pair in the E2 band region. No signs were seen at any other locations.
[00246] The clones LH15 and LH80 were injected into blastocytes of the BALB/c lineage and the embryos were implanted in the CD1 pseudopregnant female mice to load them. Male chimeras were mated with EIIa-cre mice with a C57BL/6 background to remove the neomycin resistance cassette and mice homozygous for the human 4-1BB gene were used in the study. Agonist mAb-mediated lymphocyte proliferation against 4-1BB
[00247] The ability of agonist mAbs against 4-1BB to induce lymphocyte proliferation was evaluated in 4-1BB knock in mice. 4-1BB knock in mice were dosed by intraperitoneal injection with 30 mg/kg MOR7480.1 on Study Day 0 (for animals with weekly administration, mAb injections against 4-1BB were given on Day 0 and Day). 24 hours before sample collection, an intraperitoneal injection with 2 mg of BrdU was applied to the animals. On the indicated post-dose day, peripheral blood samples were collected by intracardiac puncture. PBMC were stained with antibodies against CD3, CD4, CD8 and BrdU and evaluated by flow cytometry. The results are shown in Panel A of Figure 7. Agonist mAb-mediated anti-tumor efficacy against 4-1BB
[00248] The antitumor activity of MOR7480.1 was evaluated in 4-1BB knock in mice using B16-OVA/luc, a melanoma strain that was constructed to express the ovalbumin model antigen (OVA) and luciferase (luc ). One million tumor cells were implanted in the flank of 4-1BB knock in mice. Animals were randomized based on tumor size or when tumors reached approximately 50-100 mm3 (usually 7-10 days after tumor inoculation) and received a single injection at the indicated dose of mAb against 4-1BB. Tumor size was assessed by measuring with a caliper two to three times a week until the end of the study. The results are shown in Panel B of Figure 7.

权利要求:
Claims (15)
[0001]
1. Antibody or antigen-binding portion thereof, characterized in that it comprises an amino acid sequence of the VH region as shown in SEQ ID NO: 43 and an amino acid sequence of the VL region as shown in SEQ ID NO: 45.
[0002]
2. An isolated antibody that binds to human 4-1BB, characterized in that said antibody comprises a heavy chain amino acid sequence as shown in SEQ ID NO: 44 and further comprises a light chain amino acid sequence shown in SEQ ID NO: 46, provided that the lysine residue at the C-terminus of SEQ ID NO: 44 is optionally absent.
[0003]
3. Isolated antibody according to claim 1 or 2, characterized in that the antibody isotype is selected from IgG1 or IgG2.
[0004]
4. Pharmaceutical composition, characterized in that it comprises an antibody or antigen-binding portion thereof, as defined in any one of claims 1 to 3, and a pharmaceutically acceptable carrier.
[0005]
5. Combination, characterized in that it comprises an antibody or antigen-binding portion thereof, as defined in any one of claims 1 to 3, and a pharmaceutically acceptable carrier in combination with an immunotherapeutic agent.
[0006]
6. Combination according to claim 5, characterized in that said immunotherapeutic agent is rituximab.
[0007]
7. Use of an antibody or antigen-binding portion thereof, as defined in any one of claims 1 to 3, characterized in that it is for the preparation of a medicine for reducing tumor growth in an individual.
[0008]
8. Use of an antibody or antigen-binding portion thereof, as defined in any one of claims 1 to 3, characterized in that it is for the preparation of a medicine for reducing metastasis in tumor cells in an individual.
[0009]
9. Use of an antibody or antigen-binding portion thereof, as defined in any one of claims 1 to 3, characterized in that it is for the preparation of a medicine to treat cancer in an individual.
[0010]
10. Use according to claim 9, characterized in that said cancer is selected from the group consisting of colorectal cancer, non-Hodgkin lymphoma, prostate cancer and melanoma.
[0011]
11. Use of the combination as defined in claim 5 or 6, characterized in that it is for the preparation of a drug for reducing tumor growth in an individual.
[0012]
12. Use of the combination as defined in claim 5 or 6, characterized in that it is for the preparation of a drug for the reduction of metastasis in tumor cells in an individual.
[0013]
13. Use of the combination as defined in claim 5 or 6, characterized in that it is for the preparation of a drug to treat cancer in an individual.
[0014]
14. Isolated nucleic acid molecule, characterized in that it comprises a nucleic acid sequence selected from SEQ ID NO: 47, 48, 49 or 50.
[0015]
15. Vector, characterized in that it comprises an isolated nucleic acid as defined in claim 14.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US10640568B2|2020-05-05|4-1BB binding molecules

---

JP2019030313A|2019-02-28|Binding molecules to human ox40 receptor

---

BR112020003601A2|2020-09-01|antibodies, polynucleotide, vector, host cell, methods for making an antibody and for treating cancer and pharmaceutical composition

---

AU2013201617B2|2014-10-09|4-1BB binding molecules

---

BRPI0820875B1|2021-10-19|ISOLATED BINDING MOLECULE, HUMAN MONOCLONAL ANTIBODY, COMPOSITION, NUCLEIC ACID MOLECULE, VECTOR AND HOST CELL

同族专利:

---

公开号 | 公开日

---

KR20130080866A|2013-07-15|

---

CN103221428A|2013-07-24|

---

CA2810359A1|2012-03-15|

---

MX2013002709A|2013-05-22|

---

DK2614082T3|2018-11-26|

---

US20120237498A1|2012-09-20|

---

TWI425005B|2014-02-01|

---

NZ729044A|2020-07-31|

---

RU2551963C2|2015-06-10|

---

PT2614082T|2018-12-03|

---

JP2019065038A|2019-04-25|

---

HK1187627A1|2014-04-11|

---

US10640568B2|2020-05-05|

---

AU2011300445B2|2014-10-09|

---

KR101527300B1|2015-06-09|

---

PE20131465A1|2014-01-04|

---

AU2016204960A1|2016-08-04|

---

NZ607710A|2014-11-28|

---

RU2013110576A|2014-10-20|

---

TWI520969B|2016-02-11|

---

TW201300413A|2013-01-01|

---

RU2710717C2|2020-01-10|

---

HK1222872A1|2017-07-14|

---

MY162737A|2017-07-14|

---

CA2810359C|2021-06-22|

---

CN103221428B|2016-02-10|

---

AR082916A1|2013-01-16|

---

US20180194851A1|2018-07-12|

---

AR114031A2|2020-07-15|

---

US9468678B2|2016-10-18|

---

TW201812011A|2018-04-01|

---

RU2015110632A3|2018-11-30|

---

MX337040B|2016-02-09|

---

US8337850B2|2012-12-25|

---

US20160369000A1|2016-12-22|

---

CN105481983A|2016-04-13|

---

TWI652345B|2019-03-01|

---

EP2614082B1|2018-10-03|

---

AU2014227437B2|2016-07-28|

---

JP2013544756A|2013-12-19|

---

SI2614082T1|2018-12-31|

---

TW201414748A|2014-04-16|

---

US20130078240A1|2013-03-28|

---

SG10201506906VA|2015-10-29|

---

AU2011300445A1|2013-03-14|

---

BR112013005699A2|2017-11-21|

---

NZ700891A|2017-05-26|

---

PL2614082T3|2019-02-28|

---

KR101527297B1|2015-06-26|

---

US20140377255A1|2014-12-25|

---

ZA201502914B|2017-08-30|

---

CO6690759A2|2013-06-17|

---

SG10201912092VA|2020-02-27|

---

AU2018201703A1|2018-04-05|

---

NZ714128A|2017-10-27|

---

IL247054A|2020-06-30|

---

AU2014227437A1|2014-10-02|

---

CN105481983B|2021-09-03|

---

IL225001A|2016-08-31|

---

JP6105470B2|2017-03-29|

---

ES2699648T3|2019-02-12|

---

IL247054D0|2016-09-29|

---

WO2012032433A1|2012-03-15|

---

MY177065A|2020-09-03|

---

EP2614082A1|2013-07-17|

---

US8821867B2|2014-09-02|

---

KR20130079533A|2013-07-10|

---

TW201625694A|2016-07-16|

---

IL250386D0|2017-03-30|

---

EP3441404A1|2019-02-13|

---

JP2017075164A|2017-04-20|

---

JP6557648B2|2019-08-07|

---

HUE041958T2|2019-06-28|

---

TWI641621B|2018-11-21|

---

RU2015110632A|2015-08-10|

---

SG188313A1|2013-04-30|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4634665A|1980-02-25|1987-01-06|The Trustees Of Columbia University In The City Of New York|Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials|

---

US5179017A|1980-02-25|1993-01-12|The Trustees Of Columbia University In The City Of New York|Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials|

---

US4399216A|1980-02-25|1983-08-16|The Trustees Of Columbia University|Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials|

---

US4816567A|1983-04-08|1989-03-28|Genentech, Inc.|Recombinant immunoglobin preparations|

---

GB8601597D0|1986-01-23|1986-02-26|Wilson R H|Nucleotide sequences|

---

GB8717430D0|1987-07-23|1987-08-26|Celltech Ltd|Recombinant dna product|

---

US5677425A|1987-09-04|1997-10-14|Celltech Therapeutics Limited|Recombinant antibody|

---

GB8809129D0|1988-04-18|1988-05-18|Celltech Ltd|Recombinant dna methods vectors and host cells|

---

ES2052027T5|1988-11-11|2005-04-16|Medical Research Council|IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING.|

---

US6291158B1|1989-05-16|2001-09-18|Scripps Research Institute|Method for tapping the immunological repertoire|

---

US6172197B1|1991-07-10|2001-01-09|Medical Research Council|Methods for producing members of specific binding pairs|

---

DE69233408T2|1991-12-02|2005-09-22|Cambridge Antibody Technology Ltd., Melbourn|Production of Antibodies on Phage Surfaces Starting from Antibody Segment Libraries.|

---

PT1024191E|1991-12-02|2008-12-22|Medical Res Council|Production of anti-self antibodies from antibody segment repertoires and displayed on phage|

---

US5714350A|1992-03-09|1998-02-03|Protein Design Labs, Inc.|Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region|

---

GB9207479D0|1992-04-06|1992-05-20|Scotgen Ltd|Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man|

---

US6765087B1|1992-08-21|2004-07-20|Vrije Universiteit Brussel|Immunoglobulins devoid of light chains|

---

WO1994025591A1|1993-04-29|1994-11-10|Unilever N.V.|PRODUCTION OF ANTIBODIES OR FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i|

---

WO1996029348A1|1995-03-23|1996-09-26|Indiana University Foundation|Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases|

---

US5994619A|1996-04-01|1999-11-30|University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus|Production of chimeric bovine or porcine animals using cultured inner cell mass cells|

---

RU2192281C2|1996-10-11|2002-11-10|Бристол-Маерс Сквибб Компани|Methods and compositions for immunomodulation|

---

GB9722131D0|1997-10-20|1997-12-17|Medical Res Council|Method|

---

EP0953639A1|1998-04-30|1999-11-03|Boehringer Ingelheim International GmbH|FAPalpha-specific antibody with improved producibility|

---

US7504490B1|1998-10-16|2009-03-17|Oscient Pharmaceuticals Corporation|Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics|

---

US20030118588A1|1999-05-22|2003-06-26|Linda Diehl|Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40|

---

DE60041119D1|1999-07-20|2009-01-29|Morphosys Ag|METHOD FOR THE PRESENTATION OF PEPTIDES / PROTEINS ON BACTERIOPHAGE PARTICLES VIA DISULPIDE BINDINGS|

---

SK287954B6|2001-01-05|2012-07-03|Pfizer Inc.|Human monoclonal antibody or antigen-binding portion thereof that specifically binds to IGF-IR, pharmaceutical composition comprising the antibody or antigen-binding portion thereof, isolated cell line producing the antibody, isolated nucleic acid molecule, vector, host cell, transgenic animal, method of making of antibody or antigen-binding portion thereof and use of the antibody and the isolated nucleic acid molecule|

---

CZ20031927A3|2001-01-09|2003-10-15|Merck Patent Gmbh|Pharmaceutical preparation based on tyrosine kinase receptor inhibitors and angiogenesis inhibitors|

---

CN1678634A|2002-06-28|2005-10-05|多曼蒂斯有限公司|Immunoglobulin single variable antigen combination area and its opposite constituent|

---

AT477280T|2001-06-28|2010-08-15|Domantis Ltd|DOUBLE-SPECIFIC LIGAND AND ITS USE|

---

CN1604795B|2001-08-17|2010-05-26|科勒制药股份公司|Combination motif immune stimulatory oligonucleotides with improved activity|

---

DE60232895D1|2001-10-09|2009-08-20|Mayo Foundation|USE OF AGONISTIC 4-1BB ANTIBODIES TO IMPROVE THE IMMUNE RESPONSE|

---

AR039067A1|2001-11-09|2005-02-09|Pfizer Prod Inc|ANTIBODIES FOR CD40|

---

AT395413T|2001-12-03|2008-05-15|Amgen Fremont Inc|ANTIBODY CATEGORIZATION BASED ON BINDING CHARACTERISTICS|

---

JP2006523090A|2002-12-27|2006-10-12|ドマンティスリミテッド|Bispecific single domain antibody specific for ligand and for ligand receptor|

---

EP2221317A3|2003-06-30|2011-07-27|Domantis Limited|PEGylated single domain antibodies |

---

PL375144A1|2002-07-30|2005-11-28|Bristol-Myers Squibb Company|Humanized antibodies against human 4-1bb|

---

AR040996A1|2002-08-19|2005-04-27|Coley Pharm Group Inc|IMMUNE STIMULATING NUCLEIC ACIDS|

---

JP2006507841A|2002-11-14|2006-03-09|ダーマコン，インコーポレイテッド|Functional and ultrafunctional siRNA|

---

AU2003290059A1|2002-12-16|2004-07-09|Herbert Schwarz|Use of cd137 antagonists for the treatment of tumors|

---

AU2004239065B2|2003-05-14|2008-05-15|Domantis Limited|A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire|

---

US7288638B2|2003-10-10|2007-10-30|Bristol-Myers Squibb Company|Fully human antibodies against human 4-1BB|

---

AR046094A1|2003-10-10|2005-11-23|Squibb Bristol Myers Co|COMPLETELY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB|

---

CA2588157A1|2004-11-17|2006-05-26|Board Of Regents, The University Of Texas System|Cancer immunotherapy incorporating p53|

---

CA2595682A1|2005-01-31|2006-08-03|Ablynx N.V.|Method for generating variable domain sequences of heavy chain antibodies|

---

US7189097B2|2005-02-11|2007-03-13|Winchester Electronics Corporation|Snap lock connector|

---

WO2006088447A1|2005-02-15|2006-08-24|Gtc Biotherapeutics, Inc.|An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof|

---

KR100694508B1|2005-05-24|2007-03-13|울산대학교 산학협력단|A composition comprising HBBK4 antibody for the treatment of cancer and the immunotherapic method for treating cancer using thereby|

---

CA2610661A1|2005-06-03|2006-12-07|Pfizer Products Inc.|Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer|

---

NZ597168A|2005-08-19|2013-07-26|Abbott Lab|Dual variable domain immunoglobin and uses thereof|

---

EP1951242A2|2005-11-22|2008-08-06|Incyte Corporation|Combination therapy for the treatment of cancer|

---

AU2006317242A1|2005-11-28|2007-05-31|Genmab A/S|Recombinant monovalent antibodies and methods for production thereof|

---

KR100745488B1|2006-07-04|2007-08-02|학교법인 울산공업학원|Pharmaceutical composition comprising the anti-4-1bb monoclonal antibody and chemotherapeutic anti-cancer agent for preventing and treating cancer disease|

---

CA2667869A1|2006-11-07|2008-05-15|Merck & Co., Inc.|Antagonists of pcsk9|

---

JP2010536335A|2007-08-13|2010-12-02|ファイザー・インク|Combinatorial motif immunostimulatory oligonucleotides with improved activity|

---

CA2949772A1|2007-12-14|2009-06-25|Pfizer Inc.|Binding molecules to the human ox40 receptor|

---

WO2009130296A2|2008-04-25|2009-10-29|Morphosys Ag|Anti-alk1 antibodies and uses thereof|

---

AU2010328347B2|2009-12-07|2015-12-17|The Board Of Trustees Of The Leland Stanford Junior University|Methods for enhancing anti-tumor antibody therapy|

---

US8745699B2|2010-05-14|2014-06-03|Authentify Inc.|Flexible quasi out of band authentication architecture|

---

CN103221428B|2010-09-09|2016-02-10|辉瑞公司|4-1BB binding molecule|

---

ES2724801T3|2011-04-19|2019-09-16|Pfizer|Combinations of anti-4-1BB antibodies and ADCC inducing antibodies for cancer treatment|CN103221428B|2010-09-09|2016-02-10|辉瑞公司|4-1BB binding molecule|

---

ES2724801T3|2011-04-19|2019-09-16|Pfizer|Combinations of anti-4-1BB antibodies and ADCC inducing antibodies for cancer treatment|

---

EP2951199A4|2013-01-31|2016-07-20|Univ Jefferson|Fusion proteins for modulating regulatory and effector t cells|

---

EP3404116A1|2013-03-15|2018-11-21|The University of Chicago|Methods and compositions related to t-cell activity|

---

WO2014163101A1|2013-04-02|2014-10-09|中外製薬株式会社|Fc region variant|

---

EP3066127A1|2013-11-06|2016-09-14|Bristol-Myers Squibb Company|Immunotherapeutic dosing regimens and combinations thereof|

---

CN105980557B|2013-12-04|2020-04-07|中外制药株式会社|Antigen binding molecules with variable antigen binding capacity depending on concentration of compound and libraries thereof|

---

AU2014369982B2|2013-12-24|2019-04-18|Bristol-Myers Squibb Company|Tricyclic compounds as anticancer agents|

---

EP3686219A1|2014-02-04|2020-07-29|Pfizer Inc|Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer|

---

KR101503341B1|2014-03-12|2015-03-18|국립암센터|Methods for isolation and proliferation of autologous cancer antigen-specific CD8+ T cells|

---

CN106413751A|2014-05-21|2017-02-15|辉瑞大药厂|Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer|

---

JP2017525753A|2014-06-06|2017-09-07|フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ．|Immunomodulator|

---

PT3151921T|2014-06-06|2019-11-21|Squibb Bristol Myers Co|Antibodies against glucocorticoid-induced tumor necrosis factor receptorand uses thereof|

---

EP3185866A1|2014-08-25|2017-07-05|Pfizer Inc.|Combination of a pd-1 antagonist and an alk inhibitor for treating cancer|

---

UY36390A|2014-11-05|2016-06-01|Flexus Biosciences Inc|MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE , ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

AR102537A1|2014-11-05|2017-03-08|Flexus Biosciences Inc|IMMUNOMODULATING AGENTS|

---

US11242319B2|2014-11-05|2022-02-08|Flexus Biosciences, Inc.|Immunoregulatory agents|

---

MX2017006624A|2014-11-21|2017-08-21|Bristol-Myers Squibb Company|Antibodies against cd73 and uses thereof.|

---

TW201630907A|2014-12-22|2016-09-01|必治妥美雅史谷比公司|TGF[beta]R antagonists|

---

US10983128B2|2015-02-05|2021-04-20|Bristol-Myers Squibb Company|CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy|

---

TW201632559A|2015-02-22|2016-09-16|索倫多醫療公司|Antibody therapeutics that bind CD137|

---

RU2714233C2|2015-02-26|2020-02-13|Мерк Патент Гмбх|Pd-1/pd-l1 inhibitors for treating cancer|

---

JP6836998B2|2015-03-02|2021-03-03|ライジェル ファーマシューティカルズ， インコーポレイテッド|TGF-β inhibitor|

---

MX2017012729A|2015-04-03|2017-11-15|Bristol-Myers Squibb Company|Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer.|

---

WO2016162505A1|2015-04-08|2016-10-13|F-Star Biotechnology Limited|Her2 binding agent therapies|

---

PL3283527T3|2015-04-13|2021-06-14|Five Prime Therapeutics, Inc.|Combination therapy for cancer|

---

ES2815683T3|2015-05-11|2021-03-30|Squibb Bristol Myers Co|Tricyclic compounds as antineoplastic agents|

---

US9725449B2|2015-05-12|2017-08-08|Bristol-Myers Squibb Company|Tricyclic compounds as anticancer agents|

---

ES2770349T3|2015-05-12|2020-07-01|Bristol-Myers Squibb Company|5H-pyrido [3,2-b] indole compounds as antineoplastic agents|

---

CA2980838A1|2015-05-18|2016-11-24|Pieris Pharmaceuticals Gmbh|Anti-cancer fusion polypeptide|

---

GB201509338D0|2015-05-29|2015-07-15|Bergenbio As|Combination therapy|

---

SG10202008304TA|2015-05-29|2020-10-29|Squibb Bristol Myers Co|Antibodies against ox40 and uses thereof|

---

US10869924B2|2015-06-16|2020-12-22|Merck Patent Gmbh|PD-L1 antagonist combination treatments|

---

BR112018000903A2|2015-07-16|2018-09-11|Biokine Therapeutics Ltd.|compositions and methods for cancer treatment|

---

EP3328861A1|2015-07-28|2018-06-06|Bristol-Myers Squibb Company|Tgf beta receptor antagonists|

---

EP3331919A1|2015-08-07|2018-06-13|GlaxoSmithKline Intellectual Property Development Limited|Combination therapy comprising anti ctla-4 antibodies|

---

KR20180042370A|2015-08-25|2018-04-25|브리스톨-마이어스 스큅 컴퍼니|TGF beta receptor antagonist|

---

WO2017049452A1|2015-09-22|2017-03-30|苏州丁孚靶点生物技术有限公司|Fully human antibody against human cd137 and use thereof|

---

US10149887B2|2015-10-23|2018-12-11|Canbas Co., Ltd.|Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment|

---

JP6936221B2|2015-11-02|2021-09-15|ファイブ プライム セラピューティクス， インコーポレイテッド|CD80 extracellular domain polypeptides and their use in cancer treatment|

---

MX2018005550A|2015-11-03|2019-07-18|Janssen Biotech Inc|Antibodies specifically binding tim-3 and their uses.|

---

GB201519481D0|2015-11-04|2015-12-16|Cancer Rec Tech Ltd|Immunomodulatory antibodies|

---

JP6983776B2|2015-11-19|2021-12-17|ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company|Antibodies to Glucocorticoid-Induced Tumor Necrosis Factor Receptorand Their Use|

---

BR112018010410A8|2015-11-23|2019-02-26|Five Prime Therapeutics Inc|method for treating cancer in a subject, composition and methods of increasing the number of nk cells and increasing the number of one or more pd-11 positive cells|

---

US10450318B2|2015-12-15|2019-10-22|Bristol-Myers Squibb Company|CXCR4 receptor antagonists|

---

SG10201912405TA|2016-01-11|2020-02-27|Inhibrx Inc|Multivalent and multispecific 41bb-binding fusion proteins|

---

WO2017130076A1|2016-01-25|2017-08-03|Pfizer Inc.|Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer|

---

EA201891983A8|2016-03-04|2020-05-28|Бристол-Майерс Сквибб Компани|COMBINED THERAPY BY ANTIBODIES TO CD73|

---

US20200377606A1|2016-04-18|2020-12-03|Celldex Therapeutics, Inc.|Agonistic antibodies that bind human cd40 and uses thereof|

---

US10696648B2|2016-05-04|2020-06-30|Bristol-Myers Squibb Company|Inhibitors of indoleamine 2,3-dioxygenase and methods of their use|

---

WO2017192844A1|2016-05-04|2017-11-09|Bristol-Myers Squibb Company|Inhibitors of indoleamine 2,3-dioxygenase and methods of their use|

---

WO2017192813A1|2016-05-04|2017-11-09|Bristol-Myers Squibb Company|Inhibitors of indoleamine 2,3-dioxygenase and methods of their use|

---

EP3452452A4|2016-05-04|2019-10-30|Bristol-Myers Squibb Company|Inhibitors of indoleamine 2,3-dioxygenase and methods of their use|

---

JP2019519485A|2016-05-04|2019-07-11|ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ|Indoleamine 2,3-dioxygenase inhibitors and methods of use thereof|

---

PE20190562A1|2016-05-27|2019-04-22|Abbvie Biotherapeutics Inc|BISPECIFIC UNION PROTEINS THAT JOIN AN IMMUNOMODULATORY PROTEIN AND A TUMOR ANTIGEN|

---

EP3464362B1|2016-05-27|2020-12-09|AbbVie Biotherapeutics Inc.|Anti-4-1bb antibodies and their uses|

---

CN109661400A|2016-06-17|2019-04-19|美真达治疗公司|For exhausting the composition and method of CD117+ cell|

---

EP3471754A1|2016-06-20|2019-04-24|Kymab Limited|Anti-pd-l1 antibodies|

---

US10077306B2|2016-07-14|2018-09-18|Bristol-Myers Squibb Company|Antibodies against TIM3 and uses thereof|

---

WO2018017633A1|2016-07-21|2018-01-25|Bristol-Myers Squibb Company|TGF Beta RECEPTOR ANTAGONISTS|

---

AU2017308590A1|2016-08-12|2019-02-14|Janssen Biotech, Inc.|Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions|

---

US11246905B2|2016-08-15|2022-02-15|President And Fellows Of Harvard College|Treating infections using IdsD from Proteus mirabilis|

---

US10751415B2|2016-08-17|2020-08-25|Compugen Ltd.|Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof|

---

CN106244611B|2016-08-23|2019-05-17|浙江普康生物技术股份有限公司|A kind of preparation method and application of cellular immunity adjuvant TSA-41|

---

BR112019005895A2|2016-09-23|2019-06-11|Merus N.V.|binding molecules that modulate a biological activity expressed by a cell|

---

TW201831690A|2016-10-31|2018-09-01|美商艾歐凡斯生物治療公司|Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion|

---

WO2019165315A1|2018-02-23|2019-08-29|Syntrix Biosystems Inc.|Method for treating cancer using chemokine antagonists alone or in combination|

---

US10660909B2|2016-11-17|2020-05-26|Syntrix Biosystems Inc.|Method for treating cancer using chemokine antagonists|

---

US10899842B2|2016-11-23|2021-01-26|Immunoah Therapeutics, Inc.|4-1BB binding proteins and uses thereof|

---

US10961239B2|2017-01-05|2021-03-30|Bristol-Myers Squibb Company|TGF beta receptor antagonists|

---

CN112210010A|2017-01-06|2021-01-12|优特力克斯有限公司|Anti-human 4-1BB antibodies and uses thereof|

---

BR112019013940A2|2017-01-06|2020-02-11|Iovance Biotherapeutics, Inc.|METHOD OF TREATING A CANCER WITH A TUMOR INFILTRANT LYMPHOCYTE POPULATION, PROCESS FOR PREPARING A TUMOR INFILTRANT LYMPHOCYTE POPULATION, TUMOR INFILTRANT LYMPHOCYTE POPULATION, AND, PHARMACEUTICAL COMPOSITION.|

---

CN110461876A|2017-01-20|2019-11-15|美真达治疗公司|For exhausting the composition and method of CD137+ cell|

---

JP6697091B2|2017-01-20|2020-05-20|アーカス バイオサイエンシズ インコーポレイティド|Azolopyrimidines for the treatment of cancer-related disorders|

---

EA201991879A1|2017-02-10|2020-02-03|Генмаб Б.В.|OPTIONS OF POLYPEPTIDES AND THEIR APPLICATION|

---

EP3775165A1|2018-03-29|2021-02-17|Iovance Biotherapeutics, Inc.|Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy|

---

EP3601353A1|2017-03-31|2020-02-05|Five Prime Therapeutics, Inc.|Combination therapy for cancer using anti-gitr antibodies|

---

AU2018253176A1|2017-04-13|2019-10-31|Agenus Inc.|Anti-CD137 antibodies and methods of use thereof|

---

SG11201909710XA|2017-04-21|2019-11-28|Kyn Therapeutics|Indole ahr inhibitors and uses thereof|

---

EP3628070B1|2017-04-28|2021-09-08|Five Prime Therapeutics, Inc.|Cd80 extracellular domain polypeptides for use in increasing central memory t cells|

---

US11066392B2|2017-05-12|2021-07-20|Bristol-Myers Squibb Company|Inhibitors of indoleamine 2,3-dioxygenase and methods of their use|

---

WO2018220446A1|2017-06-01|2018-12-06|Compugen Ltd.|Triple combination antibody therapies|

---

JP2020522516A|2017-06-05|2020-07-30|アイオバンス バイオセラピューティクス，インコーポレイテッド|Methods of using tumor-infiltrating lymphocytes in double-resistant melanoma|

---

KR20200020916A|2017-06-30|2020-02-26|브리스톨-마이어스 스큅 컴퍼니|Amorphous and Crystalline Forms of IDO Inhibitors|

---

EP3652209A2|2017-07-11|2020-05-20|Compass Therapeutics LLC|Agonist antibodies that bind human cd137 and uses thereof|

---

EP3655439A1|2017-07-20|2020-05-27|Aptevo Research and Development LLC|Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods|

---

WO2019023459A1|2017-07-28|2019-01-31|Bristol-Myers Squibb Company|Cyclic dinucleotides as anticancer agents|

---

BR112020001441A2|2017-08-01|2020-08-04|Eli Lilly And Company|anti-cd137 antibodies|

---

CN111163766A|2017-08-17|2020-05-15|医肯纳肿瘤学公司|AHR inhibitors and uses thereof|

---

CN111511762A|2017-08-21|2020-08-07|天演药业公司|anti-CD137 molecules and uses thereof|

---

KR20200042938A|2017-08-31|2020-04-24|브리스톨-마이어스 스큅 컴퍼니|Cyclic dinucleotide as an anticancer agent|

---

WO2019046496A1|2017-08-31|2019-03-07|Bristol-Myers Squibb Company|Cyclic dinucleotides as anticancer agents|

---

KR20200042939A|2017-08-31|2020-04-24|브리스톨-마이어스 스큅 컴퍼니|Cyclic dinucleotide as an anticancer agent|

---

US11203592B2|2017-10-09|2021-12-21|Bristol-Myers Squibb Company|Inhibitors of indoleamine 2,3-dioxygenase and methods of their use|

---

US20210206723A1|2017-10-09|2021-07-08|Bristol-Myers Squibb Company|Inhibitors of indoleamine 2,3-dioxygenase and methods of their use|

---

EP3470426A1|2017-10-10|2019-04-17|Numab Therapeutics AG|Multispecific antibody|

---

EP3470428A1|2017-10-10|2019-04-17|Numab Innovation AG|Antibodies targeting cd137 and methods of use thereof|

---

JP2020536897A|2017-10-10|2020-12-17|ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ|Cyclic dinucleotide as an anticancer drug|

---

AU2018348429A1|2017-10-10|2020-03-12|Numab Therapeutics AG|Multispecific antibody|

---

WO2019075090A1|2017-10-10|2019-04-18|Tilos Therapeutics, Inc.|Anti-lap antibodies and uses thereof|

---

WO2019072870A1|2017-10-10|2019-04-18|Numab Innovation Ag|Antibodies targeting cd137 and methods of use thereof|

---

CN109651507B|2017-10-12|2021-11-26|瑞阳生物科技有限公司|Excited 4-1BB monoclonal antibody|

---

CN111406063A|2017-10-16|2020-07-10|百时美施贵宝公司|Cyclic dinucleotides as anticancer agents|

---

US20210221902A1|2017-10-31|2021-07-22|Compass Therapeutics Llc|Cd137 antibodies and pd-1 antagonists and uses thereof|

---

WO2019089921A1|2017-11-01|2019-05-09|Bristol-Myers Squibb Company|Immunostimulatory agonistic antibodies for use in treating cancer|

---

EP3707138A1|2017-11-06|2020-09-16|Bristol-Myers Squibb Company|Isofuranone compounds useful as hpk1 inhibitors|

---

AU2018364114A1|2017-11-08|2020-05-21|Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd.|Conjugates of biomolecule and use thereof|

---

TWI701259B|2017-11-09|2020-08-11|大陸商上海懷越生物科技有限公司|4-1BB antibody and its preparation method and application|

---

CR20200251A|2017-11-17|2020-07-17|Iovance Biotherapeutics Inc|Til expansion from fine needle aspirates and small biopsies|

---

EP3731869A4|2017-12-26|2021-09-22|Kymera Therapeutics, Inc.|Irak degraders and uses thereof|

---

CN110003332B|2018-01-05|2021-05-11|上海原能细胞医学技术有限公司|CD137 antibody and application thereof|

---

US20210070698A1|2018-01-05|2021-03-11|Bristol-Myers Squibb Company|Inhibitors of indoleamine 2,3-dioxygenase and methods of their use|

---

EP3737743A1|2018-01-08|2020-11-18|Iovance Biotherapeutics, Inc.|Processes for generating til products enriched for tumor antigen-specific t-cells|

---

WO2019136459A1|2018-01-08|2019-07-11|Iovance Biotherapeutics, Inc.|Processes for generating til products enriched for tumor antigen-specific t-cells|

---

JP2021511026A|2018-01-12|2021-05-06|ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ|Antibodies to TIM3 and its use|

---

BR112020014446A2|2018-01-15|2020-12-29|Pfizer Inc.|METHODS FOR ADMINISTERING CHEMICAL ANTIGEN RECEPTOR IMMUNOTHERAPY IN COMBINATION WITH A 4-1BB AGONIST|

---

JP2021510533A|2018-01-22|2021-04-30|江蘇恒瑞医薬股▲ふん▼有限公司|Anti-4-1BB antibody, its antigen-binding fragment, and its medical use|

---

WO2019148136A1|2018-01-29|2019-08-01|Merck Patent Gmbh|Gcn2 inhibitors and uses thereof|

---

CA3089762A1|2018-01-29|2019-08-01|Merck Patent Gmbh|Gcn2 inhibitors and uses thereof|

---

EP3752600A1|2018-02-13|2020-12-23|Iovance Biotherapeutics, Inc.|Expansion of tumor infiltrating lymphocyteswith adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists|

---

US10519187B2|2018-02-13|2019-12-31|Bristol-Myers Squibb Company|Cyclic dinucleotides as anticancer agents|

---

CA3093387A1|2018-03-08|2019-09-12|Rubius Therapeutics, Inc.|Therapeutic cell systems and methods for treating cancer and infectious diseases|

---

WO2019173587A1|2018-03-08|2019-09-12|Bristol-Myers Squibb Company|Cyclic dinucleotides as anticancer agents|

---

WO2019183040A1|2018-03-21|2019-09-26|Five Prime Therapeutics, Inc.|ANTIBODIES BINDING TO VISTA AT ACIDIC pH|

---

MA52075A|2018-03-23|2021-01-27|Lilly Co Eli|ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-L1 ANTIBODIES|

---

KR20200134288A|2018-03-23|2020-12-01|일라이 릴리 앤드 캄파니|Anti-CD137 antibody for combination with anti-PD-1 antibody|

---

EP3773720A4|2018-04-10|2022-01-05|Wuxi Biologics Shanghai Co Ltd|A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof|

---

KR20200142542A|2018-04-12|2020-12-22|브리스톨-마이어스 스큅 컴퍼니|Anticancer combination therapy with CD73 antagonist antibody and PD-1/PD-L1 axis antagonist antibody|

---

CA3094235A1|2018-04-13|2019-10-17|F. Hoffmann-La Roche Ag|Her2-targeting antigen binding molecules comprising 4-1bbl|

---

CN112292128A|2018-04-16|2021-01-29|阿瑞斯医疗有限公司|EP4 inhibitors and uses thereof|

---

AU2019257749A1|2018-04-27|2020-10-22|Iovance Biotherapeutics, Inc.|Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy|

---

WO2019213340A1|2018-05-03|2019-11-07|Bristol-Myers Squibb Company|Uracil derivatives as mer-axl inhibitors|

---

WO2019217753A1|2018-05-10|2019-11-14|Iovance Biotherapeutics, Inc.|Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy|

---

MA52889A|2018-06-15|2021-04-21|Flagship Pioneering Innovations V Inc|INCREASED IMMUNE ACTIVITY BY MODULATION OF POST-CELLULAR SIGNALING FACTORS|

---

US11180531B2|2018-06-22|2021-11-23|Bicycletx Limited|Bicyclic peptide ligands specific for Nectin-4|

---

AU2019291794A1|2018-06-27|2021-02-11|Bristol-Myers Squibb Company|Substituted naphthyridinone compounds useful as T cell activators|

---

US20210277004A1|2018-06-27|2021-09-09|Bristol-Myers Squibb Company|Naphthyridinone compounds useful as t cell activators|

---

SG11202100096XA|2018-07-09|2021-02-25|Five Prime Therapeutics Inc|Antibodies binding to ilt4|

---

US20220073617A1|2018-07-11|2022-03-10|Five Prime Therapeutics, Inc.|Antibodies Binding to Vista at Acidic pH|

---

WO2020011966A1|2018-07-12|2020-01-16|F-Star Beta Limited|Antibody molecules that bind cd137 and ox40|

---

WO2020011964A1|2018-07-12|2020-01-16|F-Star Beta Limited|Antibody molecules that bind pd-l1 and cd137|

---

GB201811404D0|2018-07-12|2018-08-29|F Star Beta Ltd|Anti-CD137 Antibodies|

---

GB201811408D0|2018-07-12|2018-08-29|F Star Beta Ltd|CD137 Binding Molecules|

---

JP2021530506A|2018-07-19|2021-11-11|イーライ リリー アンド カンパニー|Bispecific antibodies targeting immune checkpoints|

---

US20210299126A1|2018-07-23|2021-09-30|Bristol-Myers Squibb Company|Inhibitors of indoleamine 2,3-dioxygenase and methods of their use|

---

US20210355113A1|2018-07-23|2021-11-18|Bristol-Myers Squibb Company|Inhibitors of indoleamine 2,3-dioxygenase and methods of their use|

---

WO2020032230A1|2018-08-10|2020-02-13|中外製薬株式会社|Anti-cd137 antigen-binding molecule and utilization thereof|

---

US10959986B2|2018-08-29|2021-03-30|Bristol-Myers Squibb Company|Inhibitors of indoleamine 2,3-dioxygenase and methods of their use|

---

US11253525B2|2018-08-29|2022-02-22|Bristol-Myers Squibb Company|Inhibitors of indoleamine 2,3-dioxygenase and methods of their use|

---

TW202031273A|2018-08-31|2020-09-01|美商艾歐凡斯生物治療公司|Treatment of nsclc patients refractory for anti-pd-1 antibody|

---

TW202028457A|2018-09-20|2020-08-01|美商艾歐凡斯生物治療公司|Expansion of tils from cryopreserved tumor samples|

---

TW202035457A|2018-10-09|2020-10-01|瑞士商Ｎｕｍａｂ治療公司|Antibodies targeting cd137 and methods of use thereof|

---

EP3636320A1|2018-10-09|2020-04-15|Numab Therapeutics AG|Antibodies targeting cd137 and methods of use thereof|

---

JP2022504839A|2018-10-10|2022-01-13|ティロス・セラピューティクス・インコーポレイテッド|Anti-LAP antibody mutants and their use|

---

AU2019356573A1|2018-10-11|2021-05-27|Inhibrx, Inc.|PD-1 single domain antibodies and therapeutic compositions thereof|

---

JP2022506508A|2018-11-05|2022-01-17|アイオバンス バイオセラピューティクス，インコーポレイテッド|Expanded culture of TIL using AKT pathway inhibitors|

---

CA3118616A1|2018-11-05|2020-05-14|Iovance Biotherapeutics, Inc.|Selection of improved tumor reactive t-cells|

---

PE20211292A1|2018-11-05|2021-07-20|Iovance Biotherapeutics Inc|PROCESSES FOR THE PRODUCTION OF INFILTRATING TUMOR LYMPHOCYTES AND USES OF THESE IN IMMUNOTHERAPY|

---

KR20210091212A|2018-11-05|2021-07-21|이오반스 바이오테라퓨틱스, 인크.|Treatment of NSCLC Patients Refractory to Anti-PD-1 Antibodies|

---

AU2019389174A1|2018-11-30|2021-07-01|Kymera Therapeutics, Inc.|Irak degraders and uses thereof|

---

CA3123392A1|2018-12-19|2020-06-25|Iovance Biotherapeutics, Inc.|Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof|

---

EP3670659A1|2018-12-20|2020-06-24|Abivax|Biomarkers, and uses in treatment of viral infections, inflammations, or cancer|

---

WO2020128893A1|2018-12-21|2020-06-25|Pfizer Inc.|Combination treatments of cancer comprising a tlr agonist|

---

WO2020187998A1|2019-03-19|2020-09-24|Fundació Privada Institut D'investigació Oncològica De Vall Hebron|Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer|

---

CA3134144A1|2019-03-29|2020-10-08|Myst Therapeutics, Llc|Ex vivo methods for producing a t cell therapeutic and related compositions and methods|

---

WO2020201753A1|2019-04-02|2020-10-08|Bicycletx Limited|Bicycle toxin conjugates and uses thereof|

---

EP3958908A1|2019-04-24|2022-03-02|Heidelberg Pharma Research GmbH|Amatoxin antibody-drug conjugates and uses thereof|

---

WO2020227159A2|2019-05-03|2020-11-12|Flagship Pioneering Innovations V, Inc.|Methods of modulating immune activity|

---

CN114026120A|2019-05-10|2022-02-08|礼进生物医药科技（上海）有限公司|Humanized anti-CD 137 antibodies and uses thereof|

---

WO2020232029A1|2019-05-13|2020-11-19|Iovance Biotherapeutics, Inc.|Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy|

---

WO2020231713A1|2019-05-13|2020-11-19|Bristol-Myers Squibb Company|AGONISTS OF ROR GAMMAt|

---

WO2020231766A1|2019-05-13|2020-11-19|Bristol-Myers Squibb Company|AGONISTS OF ROR GAMMAt|

---

WO2020239558A1|2019-05-24|2020-12-03|Pfizer Inc.|Combination therapies using cdk inhibitors|

---

WO2020240360A1|2019-05-24|2020-12-03|Pfizer Inc.|Combination therapies using cdk inhibitors|

---

WO2020243423A1|2019-05-31|2020-12-03|Ikena Oncology, Inc.|Tead inhibitors and uses thereof|

---

AR119080A1|2019-06-04|2021-11-24|Molecular Partners Ag|MULTISPECIFIC PROTEINS|

---

WO2021026179A1|2019-08-06|2021-02-11|Bristol-Myers Squibb Company|AGONISTS OF ROR GAMMAt|

---

TW202122395A|2019-08-28|2021-06-16|美商必治妥美雅史谷比公司|Substituted pyridopyrimidinonyl compounds useful as t cell activators|

---

WO2021050964A1|2019-09-13|2021-03-18|Nimbus Saturn, Inc.|Hpk1 antagonists and uses thereof|

---

WO2021055698A1|2019-09-19|2021-03-25|Bristol-Myers Squibb Company|Antibodies binding to vista at acidic ph|

---

WO2021059136A1|2019-09-25|2021-04-01|Pfizer Inc.|Polyheterocyclic modulators of sting |

---

WO2021081378A1|2019-10-25|2021-04-29|Iovance Biotherapeutics, Inc.|Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy|

---

TW202132283A|2019-11-19|2021-09-01|美商必治妥美雅史谷比公司|Compounds useful as inhibitors of helios protein|

---

US20210253579A1|2019-11-26|2021-08-19|Ikena Oncology, Inc.|Polymorphic compounds and uses thereof|

---

WO2021108288A1|2019-11-26|2021-06-03|Bristol-Myers Squibb Company|Salts/cocrystals of -n--2--4-cyclohexyl)propanamide|

---

WO2021108727A1|2019-11-27|2021-06-03|Myst Therapeutics, Inc.|Method of producing tumor-reactive t cell composition using modulatory agents|

---

WO2021118990A1|2019-12-11|2021-06-17|Iovance Biotherapeutics, Inc.|Processes for the production of tumor infiltrating lymphocytesand methods of using the same|

---

WO2021127217A1|2019-12-17|2021-06-24|Flagship Pioneering Innovations V, Inc.|Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly|

---

TW202128176A|2019-12-18|2021-08-01|美商輝瑞股份有限公司|Once daily cancer treatment regimen with a prmt5 inhibitor|

---

WO2021133751A1|2019-12-23|2021-07-01|Bristol-Myers Squibb Company|Substituted quinazolinyl compounds useful as t cell activators|

---

TW202136254A|2019-12-23|2021-10-01|美商必治妥美雅史谷比公司|Substituted bicyclic compounds useful as t cell activators|

---

WO2021133749A1|2019-12-23|2021-07-01|Bristol-Myers Squibb Company|Substituted piperazine derivatives useful as t cell activators|

---

WO2021133752A1|2019-12-23|2021-07-01|Bristol-Myers Squibb Company|Substituted heteroaryl compounds useful as t cell activators|

---

WO2021133748A1|2019-12-23|2021-07-01|Bristol-Myers Squibb Company|Substituted quinolinonyl piperazine compounds useful as t cell activators|

---

WO2021141907A1|2020-01-06|2021-07-15|HifibioLimited|Anti-tnfr2 antibody and uses thereof|

---

WO2021139682A1|2020-01-07|2021-07-15|HifibioLimited|Anti-galectin-9 antibody and uses thereof|

---

WO2021146370A1|2020-01-15|2021-07-22|Blueprint Medicines Corporation|Map4k1 inhibitors|

---

WO2021167908A1|2020-02-17|2021-08-26|Board Of Regents, The University Of Texas System|Methods for expansion of tumor infiltrating lymphocytes and use thereof|

---

WO2021174208A1|2020-02-27|2021-09-02|Myst Therapeutics, Llc|Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof|

---

WO2021170067A1|2020-02-28|2021-09-02|上海复宏汉霖生物技术股份有限公司|Anti-cd137 construct and use thereof|

---

WO2021178488A1|2020-03-03|2021-09-10|PIC Therapeutics, Inc.|Eif4e inhibitors and uses thereof|

---

WO2021181233A2|2020-03-09|2021-09-16|Pfizer Inc.|Fusion proteins and uses thereof|

---

WO2021188769A1|2020-03-19|2021-09-23|Arcus Biosciences, Inc.|Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha|

---

WO2021194914A1|2020-03-23|2021-09-30|Bristol-Myers Squibb Company|Substituted oxoisoindoline compounds for the treatment of cancer|

---

WO2021207449A1|2020-04-09|2021-10-14|Merck Sharp & Dohme Corp.|Affinity matured anti-lap antibodies and uses thereof|

---

WO2021226061A1|2020-05-04|2021-11-11|Iovance Biotherapeutics, Inc.|Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy|

---

WO2021226085A1|2020-05-04|2021-11-11|Iovance Biotherapeutics, Inc.|Selection of improved tumor reactive t-cells|

---

WO2021229507A2|2020-05-13|2021-11-18|Pfizer Inc.|Methods, therapies and uses for treating cancer|

---

WO2021247591A1|2020-06-02|2021-12-09|Arcus Biosciences, Inc.|Antibodies to tigit|

---

WO2021258010A1|2020-06-19|2021-12-23|Gossamer Bio Services, Inc.|Oxime compounds useful as t cell activators|

---

WO2022006179A1|2020-06-29|2022-01-06|Flagship Pioneering Innovations V, Inc.|Viruses engineered to promote thanotransmission and their use in treating cancer|

---

WO2022038158A1|2020-08-17|2022-02-24|Bicycletx Limited|Bicycle conjugates specific for nectin-4 and uses thereof|

法律状态:
2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-07-02| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-09-10| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-10-27| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2021-06-08| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-08-17| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/08/2011, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US38121010P| true| 2010-09-09|2010-09-09|

---

US61/381,210|2010-09-09|

---

PCT/IB2011/053761|WO2012032433A1|2010-09-09|2011-08-26|4-1bb binding molecules|

---